≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Hypersplenism

DOID EFO Endpoint Browser PheWeb

D3_HYPERSPLENISM

hypersplenism: Overactive functioning of the spleen, resulting in excessive destruction of blood cells.

Suggest a new description

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — D73.1
  • Hospital discharge: ICD-9 — 2894
  • Cause of death: ICD-10 — D73.1
  • Cause of death: ICD-9 — 2894

2 out of 7 registries used, show all original rules.

162

4. Check minimum number of events

None

162

5. Include endpoints

None

162

6. Filter based on genotype QC (FinnGen only)

158

Control definitions (FinnGen only)

Control exclude
D3_BLOODOTHER

Extra metadata

Level in the ICD hierarchy
4
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
D73
Name in latin
Hypersplenismus

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1082 469 602
Only index persons 882 381 501
Unadjusted period prevalence (%)
Whole population 0.02 0.01 0.02
Only index persons 0.02 0.01 0.02
Median age at first event (years)
Whole population 58.66 59.57 57.67
Only index persons 56.73 57.62 56.06

-FinnGen-

Key figures

All Female Male
Number of individuals 158 72 86
Unadjusted period prevalence (%) 0.03 0.03 0.04
Median age at first event (years) 58.41 56.36 60.12

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
162
Matched controls
1620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D73.1
ICD-10 Finland
Hypersplenism
+∞
225.4
159
*
XW000
NOMESCO Finland
Bone marrow biopsy
36.7
82.6
56
23
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
11.1
52.0
77
122
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
76.4
32.6
36
6
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
382.7
32.0
31
*
D64.9
ICD-10 Finland
Anaemia, unspecified
8.2
32.0
53
91
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
6.2
30.5
95
300
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
11.8
28.6
32
33
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
7.1
24.5
44
81
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.1
22.5
48
104
C03CA01
ATC
furosemide; systemic
4.5
20.4
81
292
K74.6
ICD-10 Finland
Other and unspecified cirrhosis of liver
36.6
19.9
25
8
J01MA12
ATC
levofloxacin; systemic
4.7
19.2
60
179
R50.9
ICD-10 Finland
Fever, unspecified
4.8
18.7
56
161
JMA10
NOMESCO Finland
Transabdominal total splenectomy
106.9
18.0
19
*
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
71.2
17.1
19
*
D70.89
ICD-10 Finland
Neutropenic splenomegaly
188.6
16.8
17
*
JN4BD
NOMESCO Finland
Extensive body CT
5.1
16.3
41
101
WW500
NOMESCO Finland
Blood transfusion
13.8
16.3
28
24
C03DA01
ATC
spironolactone; oral
4.9
16.0
43
112
GD1AA
NOMESCO Finland
Thorax X-ray examination
4.0
15.8
111
569
ZX120
NOMESCO Finland
Intravenous
5.3
15.4
36
83
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
6.4
15.4
28
51
C83.80
ICD-10 Finland
B-cell lymphoma in marginal zone
+∞
14.8
14
*
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.1
13.8
26
49
JN4AD
NOMESCO Finland
Body CT examination
4.4
12.8
38
106
JN3BD
NOMESCO Finland
Extensive abdominal CT
4.6
12.1
33
86
TPH04
NOMESCO Finland
Cathetrisation of vein
3.4
11.6
57
224
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
128.8
11.6
12
*
TPH07
NOMESCO Finland
Cathetrisation of artery
4.4
11.4
32
85
A05AA02
ATC
ursodeoxycholic acid; oral
27.3
11.4
15
6
WW200
NOMESCO Finland
Immunization
14.3
11.0
18
14
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
30.4
10.9
14
5
M04AA01
ATC
allopurinol; systemic
3.7
10.4
39
128
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.1
10.3
60
259
K70.3
ICD-10 Finland
Alcoholic cirrhosis of liver
28.0
10.0
13
5
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
3.7
9.9
37
121
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
58.6
9.8
11
*
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.3
9.8
45
168
I85.0
ICD-10 Finland
Oesophageal varices with bleeding
+∞
9.5
9
*
JJ2AT
NOMESCO Finland
Biopsy of liver with ultrasound guidance
16.9
9.2
14
9
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
3.7
9.1
32
100
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
4.6
9.1
23
56
JN3AD
NOMESCO Finland
Abdominal CT examination
3.5
9.0
36
122
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.7
8.9
78
413
127
Kela drug reimbursment
Transplant complication
21.4
8.6
12
6
D80.1
ICD-10 Finland
Nonfamilial hypogammaglobulinaemia
94.8
8.5
9
*
L04AD02
ATC
tacrolimus; systemic
94.8
8.5
9
*
9689/3-C42.2
ICD-O-3
Splenic marginal zone B-cell lymphoma of spleen
+∞
8.4
8
*
K92.1
ICD-10 Finland
Melaena
5.2
8.3
18
38
C07AB07
ATC
bisoprolol; oral
2.6
8.2
94
560
JDW98
NOMESCO Finland
Other transluminal endoscopic operation on stomach or duodenum
23.4
8.1
11
5
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.5
8.1
21
52
R18
ICD-10 Finland
Ascites
14.0
8.0
13
10
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.8
7.9
19
44
C83.31
ICD-10 Finland
Diffuse lymphoma with large B cells
16.1
7.8
12
8
JMA11
NOMESCO Finland
Laparoscopic total splenectomy
47.3
7.8
9
*
JJ1LE
NOMESCO Finland
Ultrasound elastography of liver
26.4
7.7
10
*
UJF30
NOMESCO Finland
Ileoscopy through colon
3.7
7.7
27
84
JN6AD
NOMESCO Finland
CT of torso and neck
14.3
7.5
12
9
UJF32
NOMESCO Finland
Coloscopy
2.7
7.5
55
262
I81
ICD-10 Finland
Portal vein thrombosis
83.8
7.5
8
*
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
83.8
7.5
8
*
JKE98
NOMESCO Finland
Other transduodenal endoscopic operation on bile duct or ampulla of Vater
16.7
7.3
11
7
Z01.8
ICD-10 Finland
Other specified special examinations
2.7
7.3
49
223
K29.5
ICD-10 Finland
Chronic gastritis, unspecified
10.8
7.2
13
13
L01XX05
ATC
hydroxycarbamide; oral
14.6
7.0
11
8
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
8.9
7.0
14
17
C07AG02
ATC
carvedilol; oral
4.4
6.8
18
45
120
Kela drug reimbursment
Hypogammaglobulinaemia
41.9
6.8
8
*
XF603
NOMESCO Finland
Direct intraarterial blood pressure measurement
8.4
6.8
14
18
K75.9
ICD-10 Finland
Inflammatory liver disease, unspecified
23.7
6.7
9
*
A46
ICD-10 Finland
Erysipelas
2.9
6.7
38
157
R59.0
ICD-10 Finland
Localized enlarged lymph nodes
6.7
6.7
16
26
A10AE04
ATC
insulin glargine; parenteral
3.2
6.6
28
98
K76.0
ICD-10 Finland
Fatty (change of) liver, not elsewhere classified
8.0
6.6
14
19
I50.0
ICD-10 Finland
Congestive heart failure
3.9
6.5
20
56
GD1AD
NOMESCO Finland
Thorax CT examination
3.9
6.5
20
56
JA3AT
NOMESCO Finland
Cathetrisation of abdominal cavity with ultrasound guidance
15.1
6.5
10
7
L01EJ01
ATC
ruxolitinib; oral
72.6
6.5
7
*
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
72.6
6.5
7
*
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
72.6
6.5
7
*
374
Kela drug reimbursment
Ruxolitinib
72.6
6.5
7
*
174
Kela drug reimbursment
Ruxolitinib
72.6
6.5
7
*
PG1DE
NOMESCO Finland
Other extensive ultrasound examination of artery
7.6
6.4
14
20
D69.3
ICD-10 Finland
Idiopathic thrombocytopenic purpura
27.9
6.3
8
*
D83.0
ICD-10 Finland
Common variable immunodeficiency with predominant abnormalities of B-cell numbers and function
+∞
6.3
6
*
D70.82
ICD-10 Finland
Drug-induced neutropenia
+∞
6.3
6
*
A07AA11
ATC
rifaximin; oral
+∞
6.3
6
*
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
7.7
6.1
13
18
A06AD11
ATC
lactulose; oral
2.8
6.0
33
134

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Hematology
82 [38004501]
3.1e+00
3.9e+00
—
1.0e+50
—
4.8e+00
3.3e+00
cases:14.20%
controls:0.74%
cases:20.37%
controls:0.49%
—
—
cases:29.63%
controls:0.00%
—
—
cases:37.33%
controls:0.50%
cases:27.34%
controls:1.37%
23
12
139
1608
33
8
129
1612
—
48
0
114
1620
—
56
8
94
1585
35
19
93
1370
Differential panel, method unspecified - Blood
69738-3 [42870588]
1.2e+00
1.8e+00
3.6e+00
1.0e+50
3.1e+00
2.5e+00
2.0e+00
cases:16.05%
controls:5.68%
cases:18.52%
controls:3.64%
cases:20.37%
controls:0.68%
cases:4.94%
controls:0.00%
cases:16.77%
controls:0.93%
cases:29.33%
controls:3.45%
cases:42.19%
controls:9.36%
26
92
136
1528
30
59
132
1561
33
11
129
1609
8
0
154
1620
27
15
134
1600
44
55
106
1538
54
130
74
1259
Basophils/Leukocytes in Blood
30180-4 [3022096]
1.1e+00
2.1e+00
3.5e+00
1.0e+50
3.0e+00
2.5e+00
1.8e+00
cases:20.37%
controls:7.84%
cases:29.63%
controls:5.00%
cases:25.31%
controls:0.99%
cases:5.56%
controls:0.00%
cases:21.12%
controls:1.36%
cases:38.00%
controls:5.02%
cases:49.22%
controls:13.82%
33
127
129
1493
48
81
114
1539
41
16
121
1604
9
0
153
1620
34
22
127
1593
57
80
93
1513
63
192
65
1197
Monocytes/Leukocytes in Blood
26485-3 [3019069]
1.1e+00
2.1e+00
3.5e+00
1.0e+50
3.0e+00
2.4e+00
1.8e+00
cases:20.37%
controls:8.02%
cases:29.63%
controls:5.00%
cases:25.31%
controls:0.99%
cases:5.56%
controls:0.00%
cases:21.74%
controls:1.36%
cases:38.00%
controls:5.21%
cases:49.22%
controls:13.97%
33
130
129
1490
48
81
114
1539
41
16
121
1604
9
0
153
1620
35
22
126
1593
57
83
93
1510
63
194
65
1195
Eosinophils/Leukocytes in Blood
26450-7 [3006504]
1.1e+00
2.1e+00
3.6e+00
1.0e+50
3.0e+00
2.4e+00
1.7e+00
cases:20.37%
controls:7.90%
cases:29.63%
controls:4.94%
cases:25.93%
controls:0.99%
cases:5.56%
controls:0.00%
cases:21.12%
controls:1.36%
cases:38.00%
controls:5.27%
cases:48.44%
controls:14.04%
33
128
129
1492
48
80
114
1540
42
16
120
1604
9
0
153
1620
34
22
127
1593
57
84
93
1509
62
195
66
1194
Reticulocytes/Erythrocytes in Blood
4679-7 [3027945]
2.2e+00
3.0e+00
—
—
3.6e+00
2.9e+00
2.2e+00
cases:9.88%
controls:1.23%
cases:11.11%
controls:0.62%
—
—
—
—
cases:9.94%
controls:0.31%
cases:14.67%
controls:0.94%
cases:20.31%
controls:2.74%
16
20
146
1600
18
10
144
1610
—
—
16
5
145
1610
22
15
128
1578
26
38
102
1351
Lymphocytes/Leukocytes in Blood
26478-8 [3002030]
1.0e+00
2.0e+00
3.5e+00
1.0e+50
3.0e+00
2.3e+00
1.7e+00
cases:19.75%
controls:8.21%
cases:28.40%
controls:5.25%
cases:24.69%
controls:0.99%
cases:5.56%
controls:0.00%
cases:21.74%
controls:1.36%
cases:37.33%
controls:5.52%
cases:48.44%
controls:14.61%
32
133
130
1487
46
85
116
1535
40
16
122
1604
9
0
153
1620
35
22
126
1593
56
88
94
1505
62
203
66
1186
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
9.5e-01
1.9e+00
3.7e+00
1.0e+50
2.9e+00
2.3e+00
1.7e+00
cases:18.52%
controls:8.09%
cases:26.54%
controls:5.12%
cases:24.07%
controls:0.80%
cases:5.56%
controls:0.00%
cases:19.88%
controls:1.36%
cases:36.67%
controls:5.52%
cases:46.88%
controls:13.82%
30
131
132
1489
43
83
119
1537
39
13
123
1607
9
0
153
1620
32
22
129
1593
55
88
95
1505
60
192
68
1197
Outpatient Visit
OP [9202]
6.5e-01
1.2e+00
1.2e+00
5.0e+00
2.1e+00
1.7e+00
1.9e+00
cases:82.10%
controls:70.56%
cases:76.54%
controls:49.81%
cases:29.01%
controls:10.86%
cases:45.68%
controls:0.56%
cases:47.20%
controls:10.09%
cases:84.67%
controls:49.34%
cases:96.09%
controls:79.19%
133
1143
29
477
124
807
38
813
47
176
115
1444
74
9
88
1611
76
163
85
1452
127
786
23
807
123
1100
5
289
Albumin [Mass/volume] in Serum or Plasma
1751-7 [3024561]
1.0e+00
1.7e+00
3.0e+00
1.0e+50
3.3e+00
2.0e+00
1.8e+00
cases:17.90%
controls:7.41%
cases:20.37%
controls:4.26%
cases:14.81%
controls:0.86%
cases:3.09%
controls:0.00%
cases:12.42%
controls:0.50%
cases:27.33%
controls:4.77%
cases:44.53%
controls:12.24%
29
120
133
1500
33
69
129
1551
24
14
138
1606
5
0
157
1620
20
8
141
1607
41
76
109
1517
57
170
71
1219
Basophils [#/volume] in Blood
26444-0 [3006315]
8.9e-01
1.9e+00
3.2e+00
1.0e+50
2.7e+00
2.2e+00
1.7e+00
cases:17.90%
controls:8.21%
cases:27.78%
controls:5.56%
cases:22.84%
controls:1.23%
cases:4.94%
controls:0.00%
cases:18.01%
controls:1.49%
cases:36.00%
controls:5.96%
cases:51.56%
controls:15.69%
29
133
133
1487
45
90
117
1530
37
20
125
1600
8
0
154
1620
29
24
132
1591
54
95
96
1498
66
218
62
1171
Monocytes [#/volume] in Blood
26484-6 [3001604]
8.5e-01
1.9e+00
3.2e+00
1.0e+50
2.7e+00
2.2e+00
1.7e+00
cases:17.28%
controls:8.21%
cases:27.78%
controls:5.49%
cases:22.84%
controls:1.23%
cases:4.94%
controls:0.00%
cases:18.01%
controls:1.49%
cases:36.00%
controls:6.03%
cases:51.56%
controls:15.62%
28
133
134
1487
45
89
117
1531
37
20
125
1600
8
0
154
1620
29
24
132
1591
54
96
96
1497
66
217
62
1172
Lymphocytes [#/volume] in Blood
26474-7 [3019198]
8.4e-01
1.9e+00
3.2e+00
1.0e+50
2.7e+00
2.1e+00
1.7e+00
cases:17.90%
controls:8.58%
cases:28.40%
controls:5.86%
cases:24.07%
controls:1.23%
cases:4.94%
controls:0.00%
cases:18.63%
controls:1.49%
cases:36.00%
controls:6.40%
cases:52.34%
controls:16.20%
29
139
133
1481
46
95
116
1525
39
20
123
1600
8
0
154
1620
30
24
131
1591
54
102
96
1491
67
225
61
1164
Eosinophils [#/volume] in Blood
26449-9 [3013115]
8.8e-01
1.9e+00
3.1e+00
1.0e+50
2.6e+00
2.2e+00
1.8e+00
cases:18.52%
controls:8.58%
cases:29.01%
controls:5.68%
cases:23.46%
controls:1.36%
cases:5.56%
controls:0.00%
cases:18.63%
controls:1.67%
cases:36.67%
controls:6.28%
cases:53.13%
controls:16.05%
30
139
132
1481
47
92
115
1528
38
22
124
1598
9
0
153
1620
30
27
131
1588
55
100
95
1493
68
223
60
1166
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
7.0e-01
2.0e+00
3.1e+00
1.0e+50
3.2e+00
2.2e+00
1.9e+00
cases:18.52%
controls:10.12%
cases:28.40%
controls:4.94%
cases:20.99%
controls:1.23%
cases:5.56%
controls:0.00%
cases:19.25%
controls:0.93%
cases:32.67%
controls:5.21%
cases:51.56%
controls:14.33%
30
164
132
1456
46
80
116
1540
34
20
128
1600
9
0
153
1620
31
15
130
1600
49
83
101
1510
66
199
62
1190
Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma by Lactate to pyruvate reaction
14804-9 [3022250]
2.1e+00
3.3e+00
—
—
—
3.7e+00
2.8e+00
cases:9.88%
controls:1.30%
cases:16.05%
controls:0.68%
—
—
—
—
—
—
cases:20.67%
controls:0.63%
cases:28.13%
controls:2.38%
16
21
146
1599
26
11
136
1609
—
—
—
31
10
119
1583
36
33
92
1356
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
9.9e-01
1.6e+00
2.8e+00
—
3.2e+00
1.7e+00
1.5e+00
cases:16.05%
controls:6.60%
cases:14.20%
controls:3.21%
cases:8.64%
controls:0.56%
—
—
cases:8.07%
controls:0.37%
cases:14.00%
controls:2.82%
cases:32.81%
controls:10.08%
26
107
136
1513
23
52
139
1568
14
9
148
1611
—
13
6
148
1609
21
45
129
1548
42
140
86
1249
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.0e+00
1.8e+00
2.9e+00
—
2.9e+00
1.5e+00
1.4e+00
cases:16.67%
controls:6.85%
cases:17.90%
controls:3.46%
cases:8.64%
controls:0.49%
—
—
cases:8.70%
controls:0.50%
cases:18.00%
controls:4.52%
cases:35.94%
controls:12.67%
27
111
135
1509
29
56
133
1564
14
8
148
1612
—
14
8
147
1607
27
72
123
1521
46
176
82
1213
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
9.2e-01
1.9e+00
3.1e+00
—
2.8e+00
1.5e+00
1.4e+00
cases:16.67%
controls:7.41%
cases:20.37%
controls:3.83%
cases:9.88%
controls:0.49%
—
—
cases:9.94%
controls:0.68%
cases:19.33%
controls:4.96%
cases:39.84%
controls:14.11%
27
120
135
1500
33
62
129
1558
16
8
146
1612
—
16
11
145
1604
29
79
121
1514
51
196
77
1193
Thorax X-ray examination
GD1AA [2001303617]
1.2e+00
1.5e+00
2.7e+00
1.0e+50
2.0e+00
2.0e+00
1.7e+00
cases:21.60%
controls:7.84%
cases:14.20%
controls:3.58%
cases:6.79%
controls:0.49%
cases:6.17%
controls:0.00%
cases:3.73%
controls:0.50%
cases:18.00%
controls:2.89%
cases:32.81%
controls:8.50%
35
127
127
1493
23
58
139
1562
11
8
151
1612
10
0
152
1620
6
8
155
1607
27
46
123
1547
42
118
86
1271
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
1.1e+00
1.9e+00
2.6e+00
—
2.2e+00
1.9e+00
1.1e+00
cases:16.05%
controls:5.80%
cases:16.05%
controls:2.90%
cases:8.02%
controls:0.62%
—
—
cases:7.45%
controls:0.87%
cases:21.33%
controls:3.83%
cases:32.03%
controls:13.46%
26
94
136
1526
26
47
136
1573
13
10
149
1610
—
12
14
149
1601
32
61
118
1532
41
187
87
1202
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.9e-01
1.7e+00
2.8e+00
1.0e+50
2.4e+00
2.0e+00
1.9e+00
cases:15.43%
controls:10.06%
cases:29.01%
controls:6.85%
cases:24.07%
controls:1.85%
cases:6.17%
controls:0.00%
cases:19.88%
controls:2.23%
cases:37.33%
controls:7.34%
cases:56.25%
controls:15.98%
25
163
137
1457
47
111
115
1509
39
30
123
1590
10
0
152
1620
32
36
129
1579
56
117
94
1476
72
222
56
1167
Internal Medicine
11 [38004456]
1.1e+00
1.7e+00
2.4e+00
—
2.4e+00
1.7e+00
1.5e+00
cases:43.21%
controls:20.74%
cases:35.80%
controls:9.38%
cases:9.88%
controls:0.99%
—
—
cases:16.15%
controls:1.73%
cases:37.33%
controls:9.79%
cases:53.13%
controls:20.30%
70
336
92
1284
58
152
104
1468
16
16
146
1604
—
26
28
135
1587
56
156
94
1437
68
282
60
1107
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
1.9e+00
2.2e+00
1.0e+50
—
1.0e+50
3.3e+00
3.1e+00
cases:5.56%
controls:0.86%
cases:5.56%
controls:0.62%
cases:4.94%
controls:0.00%
—
—
cases:3.11%
controls:0.00%
cases:8.00%
controls:0.31%
cases:17.97%
controls:1.01%
9
14
153
1606
9
10
153
1610
8
0
154
1620
—
5
0
156
1615
12
5
138
1588
23
14
105
1375
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
5.2e-01
1.6e+00
3.2e+00
—
2.9e+00
1.6e+00
1.2e+00
cases:23.46%
controls:15.37%
cases:29.63%
controls:7.84%
cases:22.22%
controls:1.17%
—
—
cases:11.80%
controls:0.74%
cases:30.67%
controls:8.41%
cases:50.78%
controls:23.83%
38
249
124
1371
48
127
114
1493
36
19
126
1601
—
19
12
142
1603
46
134
104
1459
65
331
63
1058
Abdominal ultrasound examination
JN3AE [2001305555]
1.8e+00
2.5e+00
—
1.0e+50
—
3.0e+00
3.1e+00
cases:7.41%
controls:1.30%
cases:8.64%
controls:0.74%
—
—
cases:4.94%
controls:0.00%
—
—
cases:9.33%
controls:0.50%
cases:21.88%
controls:1.30%
12
21
150
1599
14
12
148
1608
—
8
0
154
1620
—
14
8
136
1585
28
18
100
1371
Gastroenterology
10 [38004455]
1.0e+00
2.3e+00
2.2e+00
1.0e+50
—
2.7e+00
2.0e+00
cases:15.43%
controls:6.11%
cases:19.14%
controls:2.35%
cases:7.41%
controls:0.86%
cases:8.64%
controls:0.00%
—
—
cases:26.67%
controls:2.45%
cases:31.25%
controls:5.62%
25
99
137
1521
31
38
131
1582
12
14
150
1606
14
0
148
1620
—
40
39
110
1554
40
78
88
1311
Upper gastrointestinal surgery
106 [44777669]
2.9e-01
1.3e+00
2.8e+00
—
2.8e+00
1.7e+00
1.6e+00
cases:11.73%
controls:9.07%
cases:13.58%
controls:4.07%
cases:6.79%
controls:0.43%
—
—
cases:9.32%
controls:0.62%
cases:18.67%
controls:4.21%
cases:32.03%
controls:8.64%
19
147
143
1473
22
66
140
1554
11
7
151
1613
—
15
10
146
1605
28
67
122
1526
41
120
87
1269
Protein electrophoresis panel - Serum or Plasma
24351-9 [3004588]
1.9e+00
3.3e+00
—
—
—
2.4e+00
2.6e+00
cases:4.94%
controls:0.80%
cases:8.02%
controls:0.31%
—
—
—
—
—
—
cases:6.00%
controls:0.56%
cases:9.38%
controls:0.79%
8
13
154
1607
13
5
149
1615
—
—
—
9
9
141
1584
12
11
116
1378
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
5.3e-01
1.5e+00
2.7e+00
1.0e+50
2.6e+00
1.6e+00
1.5e+00
cases:25.93%
controls:17.04%
cases:33.95%
controls:10.00%
cases:26.54%
controls:2.28%
cases:6.17%
controls:0.00%
cases:20.50%
controls:1.86%
cases:36.67%
controls:10.55%
cases:60.94%
controls:26.13%
42
276
120
1344
55
162
107
1458
43
37
119
1583
10
0
152
1620
33
30
128
1585
55
168
95
1425
78
363
50
1026
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
6.4e-01
1.5e+00
3.0e+00
1.0e+50
2.6e+00
1.6e+00
1.4e+00
cases:6.79%
controls:3.70%
cases:8.64%
controls:2.16%
cases:9.88%
controls:0.56%
cases:3.09%
controls:0.00%
cases:6.83%
controls:0.56%
cases:11.33%
controls:2.57%
cases:22.66%
controls:6.98%
11
60
151
1560
14
35
148
1585
16
9
146
1611
5
0
157
1620
11
9
150
1606
17
41
133
1552
29
97
99
1292
IgG [Mass/volume] in Serum or Plasma
2465-3 [3005719]
1.7e+00
2.2e+00
1.0e+50
—
—
3.1e+00
2.9e+00
cases:7.41%
controls:1.48%
cases:6.79%
controls:0.80%
cases:6.17%
controls:0.00%
—
—
—
—
cases:11.33%
controls:0.56%
cases:21.88%
controls:1.44%
12
24
150
1596
11
13
151
1607
10
0
152
1620
—
—
17
9
133
1584
28
20
100
1369
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
9.9e-01
1.8e+00
—
1.0e+50
2.9e+00
2.2e+00
1.9e+00
cases:11.73%
controls:4.69%
cases:11.73%
controls:2.22%
—
—
cases:5.56%
controls:0.00%
cases:5.59%
controls:0.31%
cases:15.33%
controls:1.95%
cases:29.69%
controls:5.76%
19
76
143
1544
19
36
143
1584
—
9
0
153
1620
9
5
152
1610
23
31
127
1562
38
80
90
1309
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
1.3e+00
2.2e+00
—
—
2.3e+00
2.5e+00
1.4e+00
cases:12.35%
controls:3.64%
cases:12.35%
controls:1.48%
—
—
—
—
cases:4.97%
controls:0.50%
cases:15.33%
controls:1.44%
cases:22.66%
controls:7.06%
20
59
142
1561
20
24
142
1596
—
—
8
8
153
1607
23
23
127
1570
29
98
99
1291
INR in Blood by Coagulation assay
34714-6 [3032080]
8.4e-01
1.5e+00
2.2e+00
1.0e+50
1.6e+00
1.9e+00
1.3e+00
cases:16.05%
controls:7.65%
cases:17.28%
controls:4.26%
cases:12.35%
controls:1.48%
cases:3.70%
controls:0.00%
cases:8.07%
controls:1.73%
cases:26.67%
controls:5.34%
cases:39.84%
controls:14.76%
26
124
136
1496
28
69
134
1551
20
24
142
1596
6
0
156
1620
13
28
148
1587
40
85
110
1508
51
205
77
1184
pH of Serum or Plasma
2753-2 [3018418]
8.3e-01
1.7e+00
2.7e+00
—
2.3e+00
1.4e+00
1.3e+00
cases:9.26%
controls:4.26%
cases:11.73%
controls:2.28%
cases:4.32%
controls:0.31%
—
—
cases:4.97%
controls:0.50%
cases:10.00%
controls:2.76%
cases:24.22%
controls:8.14%
15
69
147
1551
19
37
143
1583
7
5
155
1615
—
8
8
153
1607
15
44
135
1549
31
113
97
1276
Prealbumin [Mass/volume] in Serum or Plasma
14338-8 [3013742]
1.5e+00
2.4e+00
—
—
—
2.6e+00
2.8e+00
cases:6.17%
controls:1.42%
cases:8.02%
controls:0.80%
—
—
—
—
—
—
cases:8.67%
controls:0.69%
cases:22.66%
controls:1.80%
10
23
152
1597
13
13
149
1607
—
—
—
13
11
137
1582
29
25
99
1364
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
5.6e-01
1.1e+00
2.8e+00
—
2.3e+00
1.9e+00
1.1e+00
cases:12.35%
controls:7.47%
cases:8.64%
controls:3.02%
cases:5.56%
controls:0.37%
—
—
cases:4.35%
controls:0.43%
cases:16.67%
controls:2.95%
cases:24.22%
controls:9.86%
20
121
142
1499
14
49
148
1571
9
6
153
1614
—
7
7
154
1608
25
47
125
1546
31
137
97
1252
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
1.8e+00
2.1e+00
—
—
—
3.2e+00
1.9e+00
cases:9.26%
controls:1.67%
cases:6.79%
controls:0.86%
—
—
—
—
—
—
cases:14.00%
controls:0.63%
cases:21.09%
controls:3.74%
15
27
147
1593
11
14
151
1606
—
—
—
21
10
129
1583
27
52
101
1337
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
7.7e-01
1.7e+00
2.8e+00
—
2.3e+00
1.3e+00
8.6e-01
cases:12.35%
controls:6.11%
cases:12.35%
controls:2.47%
cases:4.94%
controls:0.31%
—
—
cases:6.83%
controls:0.74%
cases:10.00%
controls:2.82%
cases:25.78%
controls:12.81%
20
99
142
1521
20
40
142
1580
8
5
154
1615
—
11
12
150
1603
15
45
135
1548
33
178
95
1211
Inpatient Hospital
21 [8717]
6.9e-01
1.2e+00
1.8e+00
1.0e+50
3.0e+00
1.3e+00
1.1e+00
cases:45.68%
controls:29.57%
cases:27.16%
controls:10.31%
cases:6.79%
controls:1.23%
cases:20.99%
controls:0.00%
cases:17.39%
controls:1.05%
cases:28.00%
controls:9.86%
cases:45.31%
controls:22.25%
74
479
88
1141
44
167
118
1453
11
20
151
1600
34
0
128
1620
28
17
133
1598
42
157
108
1436
58
309
70
1080
Normoblasts [#/volume] in Blood
715-3 [3021589]
5.7e-01
1.3e+00
2.6e+00
—
2.4e+00
1.5e+00
1.1e+00
cases:11.73%
controls:6.98%
cases:17.28%
controls:5.37%
cases:15.43%
controls:1.36%
—
—
cases:13.66%
controls:1.36%
cases:22.67%
controls:6.03%
cases:32.03%
controls:13.61%
19
113
143
1507
28
87
134
1533
25
22
137
1598
—
22
22
139
1593
34
96
116
1497
41
189
87
1200
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
8.6e-01
1.1e+00
2.0e+00
—
2.6e+00
1.1e+00
1.1e+00
cases:20.37%
controls:9.75%
cases:13.58%
controls:4.88%
cases:6.17%
controls:0.86%
—
—
cases:6.21%
controls:0.50%
cases:16.00%
controls:5.84%
cases:38.28%
controls:17.35%
33
158
129
1462
22
79
140
1541
10
14
152
1606
—
10
8
151
1607
24
93
126
1500
49
241
79
1148
furosemide; oral, parenteral
C03CA01 [21601518]
1.1e+00
1.2e+00
1.8e+00
—
1.5e+00
1.4e+00
1.7e+00
cases:14.20%
controls:5.00%
cases:14.20%
controls:4.63%
cases:7.41%
controls:1.36%
—
—
cases:6.83%
controls:1.55%
cases:16.67%
controls:4.58%
cases:28.91%
controls:7.13%
23
81
139
1539
23
75
139
1545
12
22
150
1598
—
11
25
150
1590
25
73
125
1520
37
99
91
1290
Transferrin [Mass/volume] in Serum or Plasma
3034-6 [3004789]
1.8e+00
2.1e+00
—
—
—
2.9e+00
1.9e+00
cases:9.88%
controls:1.73%
cases:6.79%
controls:0.93%
—
—
—
—
—
—
cases:13.33%
controls:0.82%
cases:21.09%
controls:3.89%
16
28
146
1592
11
15
151
1605
—
—
—
20
13
130
1580
27
54
101
1335
Reticulocytes [#/volume] in Blood
14196-0 [3023520]
2.7e+00
—
1.0e+50
—
—
3.4e+00
2.5e+00
cases:8.02%
controls:0.56%
—
—
cases:7.41%
controls:0.00%
—
—
—
—
cases:12.00%
controls:0.44%
cases:16.41%
controls:1.66%
13
9
149
1611
—
12
0
150
1620
—
—
18
7
132
1586
21
23
107
1366
Iron [Moles/volume] in Serum or Plasma
14798-3 [3022948]
1.9e+00
2.0e+00
—
—
—
2.9e+00
1.8e+00
cases:11.11%
controls:1.91%
cases:6.79%
controls:0.99%
—
—
—
—
—
—
cases:13.33%
controls:0.82%
cases:21.09%
controls:4.18%
18
31
144
1589
11
16
151
1604
—
—
—
20
13
130
1580
27
58
101
1331
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
2.7e-01
1.1e+00
2.6e+00
—
2.4e+00
1.2e+00
1.2e+00
cases:31.48%
controls:26.05%
cases:35.80%
controls:16.11%
cases:30.25%
controls:3.02%
—
—
cases:22.36%
controls:2.54%
cases:41.33%
controls:17.45%
cases:71.09%
controls:43.41%
51
422
111
1198
58
261
104
1359
49
49
113
1571
—
36
41
125
1574
62
278
88
1315
91
603
37
786
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
5.2e-01
1.4e+00
2.6e+00
—
2.5e+00
1.3e+00
7.3e-01
cases:20.37%
controls:13.21%
cases:20.99%
controls:6.23%
cases:12.96%
controls:1.05%
—
—
cases:9.32%
controls:0.87%
cases:18.00%
controls:5.90%
cases:38.28%
controls:23.04%
33
214
129
1406
34
101
128
1519
21
17
141
1603
—
15
14
146
1601
27
94
123
1499
49
320
79
1069
allopurinol; oral, parenteral
M04AA01 [21604131]
1.3e+00
1.7e+00
2.3e+00
—
1.7e+00
1.7e+00
1.3e+00
cases:8.02%
controls:2.35%
cases:9.26%
controls:1.79%
cases:4.32%
controls:0.43%
—
—
cases:3.11%
controls:0.56%
cases:9.33%
controls:1.88%
cases:12.50%
controls:3.74%
13
38
149
1582
15
29
147
1591
7
7
155
1613
—
5
9
156
1606
14
30
136
1563
16
52
112
1337
Outpatient Hospital
22 [8756]
5.7e-01
1.1e+00
1.9e+00
1.0e+50
2.6e+00
1.5e+00
1.2e+00
cases:34.57%
controls:23.02%
cases:19.75%
controls:7.72%
cases:5.56%
controls:0.86%
cases:12.96%
controls:0.00%
cases:9.32%
controls:0.74%
cases:23.33%
controls:6.21%
cases:38.28%
controls:16.34%
56
373
106
1247
32
125
130
1495
9
14
153
1606
21
0
141
1620
15
12
146
1603
35
99
115
1494
49
227
79
1162
Infectious Disease
44 [38004484]
1.8e+00
2.1e+00
—
—
1.0e+50
2.2e+00
2.1e+00
cases:8.64%
controls:1.54%
cases:6.79%
controls:0.93%
—
—
—
—
cases:6.21%
controls:0.00%
cases:10.00%
controls:1.19%
cases:12.50%
controls:1.66%
14
25
148
1595
11
15
151
1605
—
—
10
0
151
1615
15
19
135
1574
16
23
112
1366
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.3e+00
2.1e+00
—
—
1.0e+50
2.7e+00
2.1e+00
cases:14.81%
controls:4.38%
cases:9.88%
controls:1.30%
—
—
—
—
cases:4.97%
controls:0.00%
cases:16.00%
controls:1.32%
cases:23.44%
controls:3.74%
24
71
138
1549
16
21
146
1599
—
—
8
0
153
1615
24
21
126
1572
30
52
98
1337
Leukocytes [#/volume] in Urine
30405-5 [3018095]
1.1e+00
8.3e-01
2.5e+00
1.0e+50
2.2e+00
1.3e+00
1.1e+00
cases:11.73%
controls:4.38%
cases:6.17%
controls:2.78%
cases:4.32%
controls:0.37%
cases:4.32%
controls:0.00%
cases:3.73%
controls:0.43%
cases:12.67%
controls:3.89%
cases:27.34%
controls:11.02%
19
71
143
1549
10
45
152
1575
7
6
155
1614
7
0
155
1620
6
7
155
1608
19
62
131
1531
35
153
93
1236
Emergency Room Visit
ER [9203]
4.8e-01
1.3e+00
2.3e+00
1.0e+50
2.2e+00
8.4e-01
1.4e+00
cases:45.06%
controls:33.58%
cases:33.33%
controls:11.54%
cases:14.20%
controls:1.60%
cases:17.90%
controls:0.00%
cases:11.80%
controls:1.42%
cases:25.33%
controls:12.74%
cases:61.72%
controls:29.16%
73
544
89
1076
54
187
108
1433
23
26
139
1594
29
0
133
1620
19
23
142
1592
38
203
112
1390
79
405
49
984
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
1.3e+00
1.5e+00
2.7e+00
—
—
1.7e+00
8.8e-01
cases:11.11%
controls:3.40%
cases:8.02%
controls:1.85%
cases:4.32%
controls:0.31%
—
—
—
—
cases:11.33%
controls:2.26%
cases:18.75%
controls:8.71%
18
55
144
1565
13
30
149
1590
7
5
155
1615
—
—
17
36
133
1557
24
121
104
1268
Bilirubin.conjugated [Moles/volume] in Serum or Plasma
29760-6 [3005772]
1.8e+00
1.9e+00
—
—
—
2.4e+00
1.8e+00
cases:9.88%
controls:1.73%
cases:7.41%
controls:1.17%
—
—
—
—
—
—
cases:7.33%
controls:0.69%
cases:14.84%
controls:2.81%
16
28
146
1592
12
19
150
1601
—
—
—
11
11
139
1582
19
39
109
1350
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.1e+00
2.0e+00
2.4e+00
1.0e+50
—
1.3e+00
1.1e+00
cases:14.20%
controls:5.00%
cases:12.35%
controls:1.91%
cases:7.41%
controls:0.74%
cases:3.70%
controls:0.00%
—
—
cases:10.00%
controls:2.95%
cases:20.31%
controls:7.49%
23
81
139
1539
20
31
142
1589
12
12
150
1608
6
0
156
1620
—
15
47
135
1546
26
104
102
1285
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
6.5e-01
1.1e+00
2.1e+00
—
2.1e+00
1.3e+00
1.1e+00
cases:20.99%
controls:12.22%
cases:17.90%
controls:6.54%
cases:7.41%
controls:0.99%
—
—
cases:8.70%
controls:1.11%
cases:22.67%
controls:7.22%
cases:45.31%
controls:21.45%
34
198
128
1422
29
106
133
1514
12
16
150
1604
—
14
18
147
1597
34
115
116
1478
58
298
70
1091
Laboratory Visit
OMOP4822461 [32036]
2.4e-01
5.1e-01
1.8e+00
4.3e+00
1.6e+00
5.6e-01
5.2e-01
cases:43.83%
controls:38.02%
cases:46.91%
controls:34.63%
cases:43.83%
controls:10.99%
cases:20.99%
controls:0.37%
cases:38.51%
controls:10.84%
cases:52.67%
controls:38.79%
cases:76.56%
controls:65.95%
71
616
91
1004
76
561
86
1059
71
178
91
1442
34
6
128
1614
62
175
99
1440
79
618
71
975
98
916
30
473
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
1.3e+00
1.8e+00
—
—
—
2.6e+00
2.1e+00
cases:7.41%
controls:2.16%
cases:5.56%
controls:0.99%
—
—
—
—
—
—
cases:7.33%
controls:0.56%
cases:17.19%
controls:2.59%
12
35
150
1585
9
16
153
1604
—
—
—
11
9
139
1584
22
36
106
1353
Protein [Mass/volume] in Serum or Plasma
2885-2 [3020630]
1.5e+00
2.7e+00
—
—
—
2.6e+00
2.3e+00
cases:4.32%
controls:0.99%
cases:6.79%
controls:0.49%
—
—
—
—
—
—
cases:6.67%
controls:0.50%
cases:11.72%
controls:1.30%
7
16
155
1604
11
8
151
1612
—
—
—
10
8
140
1585
15
18
113
1371
Anaemia, unspecified
D64.9 [45600610]
1.9e+00
3.2e+00
1.0e+50
—
1.0e+50
2.2e+00
1.3e+00
cases:6.79%
controls:1.05%
cases:11.73%
controls:0.56%
cases:4.94%
controls:0.00%
—
—
cases:3.11%
controls:0.00%
cases:6.00%
controls:0.69%
cases:6.25%
controls:1.73%
11
17
151
1603
19
9
143
1611
8
0
154
1620
—
5
0
156
1615
9
11
141
1582
8
24
120
1365
Metamyelocytes/Leukocytes in Blood
28541-1 [3002179]
1.6e+00
2.5e+00
—
—
1.0e+50
2.6e+00
2.2e+00
cases:3.09%
controls:0.62%
cases:5.56%
controls:0.49%
—
—
—
—
cases:5.59%
controls:0.00%
cases:8.67%
controls:0.69%
cases:12.50%
controls:1.58%
5
10
157
1610
9
8
153
1612
—
—
9
0
152
1615
13
11
137
1582
16
22
112
1367
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
6.5e-01
1.2e+00
2.0e+00
—
1.8e+00
1.3e+00
9.5e-01
cases:19.14%
controls:10.99%
cases:16.05%
controls:5.25%
cases:5.56%
controls:0.80%
—
—
cases:6.21%
controls:1.11%
cases:20.67%
controls:6.59%
cases:41.41%
controls:21.53%
31
178
131
1442
26
85
136
1535
9
13
153
1607
—
10
18
151
1597
31
105
119
1488
53
299
75
1090
Bacteria identified in Blood by Culture
600-7 [3023368]
1.7e+00
2.0e+00
—
1.0e+50
—
1.9e+00
1.6e+00
cases:11.73%
controls:2.35%
cases:9.26%
controls:1.36%
—
—
cases:4.32%
controls:0.00%
—
—
cases:12.00%
controls:2.07%
cases:24.22%
controls:5.98%
19
38
143
1582
15
22
147
1598
—
7
0
155
1620
—
18
33
132
1560
31
83
97
1306
Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1742-6 [3006923]
3.4e-01
9.7e-01
2.4e+00
—
2.0e+00
9.4e-01
7.6e-01
cases:36.42%
controls:28.95%
cases:40.12%
controls:20.25%
cases:32.10%
controls:4.20%
—
—
cases:22.98%
controls:3.84%
cases:43.33%
controls:22.91%
cases:69.53%
controls:51.62%
59
469
103
1151
65
328
97
1292
52
68
110
1552
—
37
62
124
1553
65
365
85
1228
89
717
39
672
Urinalysis microscopic panel [#/volume] - Urine by Automated count
50554-5 [3029287]
9.8e-01
1.2e+00
—
1.0e+50
2.2e+00
1.4e+00
1.2e+00
cases:11.73%
controls:4.75%
cases:8.02%
controls:2.59%
—
—
cases:3.70%
controls:0.00%
cases:4.35%
controls:0.50%
cases:12.00%
controls:3.20%
cases:27.34%
controls:10.22%
19
77
143
1543
13
42
149
1578
—
6
0
156
1620
7
8
154
1607
18
51
132
1542
35
142
93
1247
Iron deficiency anaemia, unspecified
D50.9 [45605373]
1.5e+00
2.8e+00
—
—
—
2.4e+00
1.8e+00
cases:3.09%
controls:0.68%
cases:5.56%
controls:0.37%
—
—
—
—
—
—
cases:4.67%
controls:0.44%
cases:6.25%
controls:1.08%
5
11
157
1609
9
6
153
1614
—
—
—
7
7
143
1586
8
15
120
1374
Emergency Medicine
93 [38004510]
5.0e-01
1.1e+00
2.0e+00
1.0e+50
2.0e+00
1.1e+00
7.1e-01
cases:17.28%
controls:11.30%
cases:16.05%
controls:5.74%
cases:8.64%
controls:1.23%
cases:11.11%
controls:0.00%
cases:6.83%
controls:0.99%
cases:18.67%
controls:7.22%
cases:39.06%
controls:23.90%
28
183
134
1437
26
93
136
1527
14
20
148
1600
18
0
144
1620
11
16
150
1599
28
115
122
1478
50
332
78
1057
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.0e+00
2.3e+00
—
—
—
2.1e+00
1.5e+00
cases:10.49%
controls:4.01%
cases:11.73%
controls:1.30%
—
—
—
—
—
—
cases:14.67%
controls:2.01%
cases:24.22%
controls:6.77%
17
65
145
1555
19
21
143
1599
—
—
—
22
32
128
1561
31
94
97
1295
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
3.3e-01
9.0e-01
2.2e+00
—
2.0e+00
1.0e+00
7.4e-01
cases:35.19%
controls:28.02%
cases:38.27%
controls:20.06%
cases:29.63%
controls:4.38%
—
—
cases:22.98%
controls:3.84%
cases:44.00%
controls:22.16%
cases:67.19%
controls:49.39%
57
454
105
1166
62
325
100
1295
48
71
114
1549
—
37
62
124
1553
66
353
84
1240
86
686
42
703
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
2.9e-01
9.2e-01
2.2e+00
—
2.0e+00
1.0e+00
6.6e-01
cases:33.95%
controls:27.78%
cases:38.27%
controls:19.81%
cases:29.01%
controls:4.14%
—
—
cases:22.36%
controls:3.78%
cases:44.00%
controls:21.97%
cases:64.84%
controls:48.88%
55
450
107
1170
62
321
100
1299
47
67
115
1553
—
36
61
125
1554
66
350
84
1243
83
679
45
710
Myelocytes/Leukocytes in Blood
26498-6 [3017181]
1.5e+00
2.4e+00
—
—
—
2.4e+00
2.1e+00
cases:3.70%
controls:0.86%
cases:6.17%
controls:0.62%
—
—
—
—
—
—
cases:8.67%
controls:0.88%
cases:14.06%
controls:1.94%
6
14
156
1606
10
10
152
1610
—
—
—
13
14
137
1579
18
27
110
1362
Supplier / Service Provider
OMOP5117446 [33004]
-4.4e-01
-2.8e-01
—
—
—
3.5e+00
3.3e+00
cases:17.90%
controls:25.25%
cases:6.79%
controls:8.77%
—
—
—
—
—
—
cases:12.67%
controls:0.44%
cases:21.09%
controls:1.01%
29
409
133
1211
11
142
151
1478
—
—
—
19
7
131
1586
27
14
101
1375
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
3.8e-01
7.3e-01
2.3e+00
—
1.8e+00
9.1e-01
9.0e-01
cases:28.40%
controls:21.30%
cases:29.63%
controls:16.85%
cases:24.07%
controls:2.96%
—
—
cases:18.63%
controls:3.53%
cases:34.67%
controls:17.64%
cases:59.38%
controls:37.22%
46
345
116
1275
48
273
114
1347
39
48
123
1572
—
30
57
131
1558
52
281
98
1312
76
517
52
872
FEV1 percent change
69983-5 [42868472]
1.4e+00
—
—
—
—
2.6e+00
2.7e+00
cases:6.17%
controls:1.54%
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.38%
cases:11.72%
controls:0.86%
10
25
152
1595
—
—
—
—
7
6
143
1587
15
12
113
1377
FVC percent change Respiratory system
69982-7 [42868471]
1.4e+00
—
—
—
—
2.6e+00
2.7e+00
cases:6.17%
controls:1.54%
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.38%
cases:11.72%
controls:0.86%
10
25
152
1595
—
—
—
—
7
6
143
1587
15
12
113
1377
Forced vital capacity [Volume] Respiratory system --post bronchodilation
19875-4 [3001668]
1.4e+00
—
—
—
—
2.6e+00
2.7e+00
cases:6.17%
controls:1.54%
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.38%
cases:11.72%
controls:0.86%
10
25
152
1595
—
—
—
—
7
6
143
1587
15
12
113
1377
FEV1 --post bronchodilation
20155-8 [3023550]
1.4e+00
—
—
—
—
2.6e+00
2.7e+00
cases:6.17%
controls:1.54%
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.38%
cases:11.72%
controls:0.86%
10
25
152
1595
—
—
—
—
7
6
143
1587
15
12
113
1377
FEV1/FVC --post bronchodilation
69970-2 [42868459]
1.4e+00
—
—
—
—
2.6e+00
2.7e+00
cases:6.17%
controls:1.54%
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.38%
cases:11.72%
controls:0.86%
10
25
152
1595
—
—
—
—
7
6
143
1587
15
12
113
1377
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
4.3e-01
1.3e+00
—
—
2.5e+00
1.5e+00
1.4e+00
cases:11.11%
controls:7.53%
cases:8.02%
controls:2.41%
—
—
—
—
cases:5.59%
controls:0.50%
cases:11.33%
controls:2.70%
cases:21.88%
controls:6.19%
18
122
144
1498
13
39
149
1581
—
—
9
8
152
1607
17
43
133
1550
28
86
100
1303
spironolactone; oral
C03DA01 [21601534]
1.5e+00
1.5e+00
—
—
—
1.7e+00
2.0e+00
cases:6.79%
controls:1.54%
cases:5.56%
controls:1.30%
—
—
—
—
—
—
cases:7.33%
controls:1.44%
cases:15.63%
controls:2.52%
11
25
151
1595
9
21
153
1599
—
—
—
11
23
139
1570
20
35
108
1354
FEV1/FVC
19926-5 [3011505]
1.5e+00
—
—
—
—
2.5e+00
2.6e+00
cases:7.41%
controls:1.79%
—
—
—
—
—
—
—
—
cases:5.33%
controls:0.44%
cases:11.72%
controls:1.01%
12
29
150
1591
—
—
—
—
8
7
142
1586
15
14
113
1375
Forced vital capacity [Volume] Respiratory system
19870-5 [3020158]
1.5e+00
—
—
—
—
2.5e+00
2.6e+00
cases:7.41%
controls:1.79%
—
—
—
—
—
—
—
—
cases:5.33%
controls:0.44%
cases:11.72%
controls:1.01%
12
29
150
1591
—
—
—
—
8
7
142
1586
15
14
113
1375
FEV1
20150-9 [3024653]
1.5e+00
—
—
—
—
2.5e+00
2.6e+00
cases:7.41%
controls:1.79%
—
—
—
—
—
—
—
—
cases:5.33%
controls:0.44%
cases:11.72%
controls:1.01%
12
29
150
1591
—
—
—
—
8
7
142
1586
15
14
113
1375
Hepatitis B virus core Ab [Presence] in Serum
16933-4 [3021879]
1.7e+00
—
—
—
1.0e+50
3.0e+00
1.8e+00
cases:7.41%
controls:1.42%
—
—
—
—
—
—
cases:4.35%
controls:0.00%
cases:7.33%
controls:0.38%
cases:10.16%
controls:1.80%
12
23
150
1597
—
—
—
7
0
154
1615
11
6
139
1587
13
25
115
1364
Promyelocytes/Leukocytes in Blood
26524-9 [3021440]
1.6e+00
2.4e+00
—
—
—
2.2e+00
2.0e+00
cases:3.70%
controls:0.80%
cases:6.17%
controls:0.62%
—
—
—
—
—
—
cases:7.33%
controls:0.88%
cases:12.50%
controls:1.87%
6
13
156
1607
10
10
152
1610
—
—
—
11
14
139
1579
16
26
112
1363
Blasts/Leukocytes in Blood
26446-5 [3025159]
1.4e+00
2.2e+00
—
—
—
2.4e+00
1.9e+00
cases:3.09%
controls:0.80%
cases:4.94%
controls:0.56%
—
—
—
—
—
—
cases:8.67%
controls:0.88%
cases:10.94%
controls:1.80%
5
13
157
1607
8
9
154
1611
—
—
—
13
14
137
1579
14
25
114
1364
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
9.2e-01
1.2e+00
2.2e+00
—
—
1.2e+00
9.5e-01
cases:15.43%
controls:6.79%
cases:10.49%
controls:3.33%
cases:3.70%
controls:0.43%
—
—
—
—
cases:12.00%
controls:3.95%
cases:27.34%
controls:12.74%
25
110
137
1510
17
54
145
1566
6
7
156
1613
—
—
18
63
132
1530
35
177
93
1212
Intravenous
ZX120 [2001311495]
1.9e+00
2.2e+00
—
—
—
1.9e+00
2.4e+00
cases:6.79%
controls:1.11%
cases:3.70%
controls:0.43%
—
—
—
—
—
—
cases:4.00%
controls:0.63%
cases:10.16%
controls:1.01%
11
18
151
1602
6
7
156
1613
—
—
—
6
10
144
1583
13
14
115
1375
Bacteria [Presence] in Urine
87829-8 [36304419]
1.3e+00
9.5e-01
—
1.0e+50
2.3e+00
1.5e+00
1.1e+00
cases:11.11%
controls:3.27%
cases:4.94%
controls:1.98%
—
—
cases:3.09%
controls:0.00%
cases:3.73%
controls:0.37%
cases:10.00%
controls:2.39%
cases:20.31%
controls:7.63%
18
53
144
1567
8
32
154
1588
—
5
0
157
1620
6
6
155
1609
15
38
135
1555
26
106
102
1283
IgA [Mass/volume] in Serum or Plasma
2458-8 [3007164]
1.1e+00
1.8e+00
—
—
—
2.5e+00
1.8e+00
cases:7.41%
controls:2.72%
cases:8.02%
controls:1.36%
—
—
—
—
—
—
cases:10.00%
controls:0.88%
cases:22.66%
controls:4.54%
12
44
150
1576
13
22
149
1598
—
—
—
15
14
135
1579
29
63
99
1326
Hepatitis C virus Ab [Presence] in Serum
16128-1 [3017143]
1.4e+00
1.3e+00
—
—
1.0e+50
2.8e+00
1.9e+00
cases:9.26%
controls:2.41%
cases:3.70%
controls:1.05%
—
—
—
—
cases:4.35%
controls:0.00%
cases:9.33%
controls:0.63%
cases:14.06%
controls:2.30%
15
39
147
1581
6
17
156
1603
—
—
7
0
154
1615
14
10
136
1583
18
32
110
1357
Fever, unspecified
R50.9 [45582716]
1.3e+00
2.2e+00
—
1.0e+50
—
2.0e+00
1.9e+00
cases:4.32%
controls:1.17%
cases:4.32%
controls:0.49%
—
—
cases:3.70%
controls:0.00%
—
—
cases:5.33%
controls:0.75%
cases:11.72%
controls:1.94%
7
19
155
1601
7
8
155
1612
—
6
0
156
1620
—
8
12
142
1581
15
27
113
1362
Hepatitis B virus surface Ag [Presence] in Serum
5195-3 [3019284]
1.2e+00
1.0e+00
—
—
—
3.0e+00
1.8e+00
cases:9.26%
controls:2.90%
cases:3.70%
controls:1.36%
—
—
—
—
—
—
cases:10.67%
controls:0.56%
cases:17.97%
controls:3.38%
15
47
147
1573
6
22
156
1598
—
—
—
16
9
134
1584
23
47
105
1342
Casts [#/volume] in Urine by Automated count
51483-6 [3030467]
1.3e+00
8.8e-01
—
1.0e+50
2.3e+00
1.4e+00
1.1e+00
cases:11.11%
controls:3.33%
cases:4.94%
controls:2.10%
—
—
cases:3.70%
controls:0.00%
cases:3.73%
controls:0.37%
cases:10.00%
controls:2.64%
cases:20.31%
controls:8.06%
18
54
144
1566
8
34
154
1586
—
6
0
156
1620
6
6
155
1609
15
42
135
1551
26
112
102
1277
HIV 1 and 2 tests - Meaningful Use set
75622-1 [46235355]
1.0e+00
1.7e+00
1.0e+50
—
—
2.8e+00
1.5e+00
cases:8.64%
controls:3.21%
cases:6.79%
controls:1.30%
cases:3.09%
controls:0.00%
—
—
—
—
cases:10.00%
controls:0.69%
cases:18.75%
controls:4.82%
14
52
148
1568
11
21
151
1599
5
0
157
1620
—
—
15
11
135
1582
24
67
104
1322
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
1.8e+00
1.7e+00
—
—
—
2.2e+00
2.0e+00
cases:5.56%
controls:0.93%
cases:4.32%
controls:0.80%
—
—
—
—
—
—
cases:6.67%
controls:0.82%
cases:14.06%
controls:2.23%
9
15
153
1605
7
13
155
1607
—
—
—
10
13
140
1580
18
31
110
1358
Erythrocytes [#/volume] in Urine
30391-7 [3002582]
1.2e+00
8.9e-01
2.3e+00
1.0e+50
2.2e+00
1.4e+00
1.2e+00
cases:11.73%
controls:3.89%
cases:5.56%
controls:2.35%
cases:3.09%
controls:0.31%
cases:4.32%
controls:0.00%
cases:3.73%
controls:0.43%
cases:11.33%
controls:3.08%
cases:25.00%
controls:9.36%
19
63
143
1557
9
38
153
1582
5
5
157
1615
7
0
155
1620
6
7
155
1608
17
49
133
1544
32
130
96
1259
Stomach Pathology biopsy report
66114-0 [40768797]
1.3e+00
2.7e+00
—
—
—
1.9e+00
1.1e+00
cases:8.02%
controls:2.35%
cases:6.17%
controls:0.43%
—
—
—
—
—
—
cases:6.00%
controls:0.94%
cases:7.81%
controls:2.81%
13
38
149
1582
10
7
152
1613
—
—
—
9
15
141
1578
10
39
118
1350
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.2e-01
8.5e-01
2.3e+00
—
1.9e+00
8.8e-01
5.4e-01
cases:39.51%
controls:34.38%
cases:45.68%
controls:26.48%
cases:40.74%
controls:6.54%
—
—
cases:31.06%
controls:6.38%
cases:51.33%
controls:30.51%
cases:72.66%
controls:60.76%
64
557
98
1063
74
429
88
1191
66
106
96
1514
—
50
103
111
1512
77
486
73
1107
93
844
35
545
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
6.5e-01
9.8e-01
—
—
2.7e+00
1.7e+00
1.5e+00
cases:9.88%
controls:5.43%
cases:4.94%
controls:1.91%
—
—
—
—
cases:4.35%
controls:0.31%
cases:10.00%
controls:2.01%
cases:22.66%
controls:6.05%
16
88
146
1532
8
31
154
1589
—
—
7
5
154
1610
15
32
135
1561
29
84
99
1305
Leukocytes [#/volume] in Blood
26464-8 [3010813]
2.2e-01
8.5e-01
2.3e+00
—
1.9e+00
8.8e-01
5.8e-01
cases:39.51%
controls:34.32%
cases:45.68%
controls:26.48%
cases:40.12%
controls:6.54%
—
—
cases:31.06%
controls:6.32%
cases:51.33%
controls:30.51%
cases:73.44%
controls:60.76%
64
556
98
1064
74
429
88
1191
65
106
97
1514
—
50
102
111
1513
77
486
73
1107
94
844
34
545
Platelets [#/volume] in Blood
26515-7 [3007461]
2.2e-01
8.4e-01
2.3e+00
—
1.9e+00
8.8e-01
5.5e-01
cases:39.51%
controls:34.32%
cases:45.68%
controls:26.54%
cases:40.12%
controls:6.54%
—
—
cases:31.06%
controls:6.38%
cases:51.33%
controls:30.38%
cases:72.66%
controls:60.62%
64
556
98
1064
74
430
88
1190
65
106
97
1514
—
50
103
111
1512
77
484
73
1109
93
842
35
547
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
2.2e-01
8.4e-01
2.3e+00
—
1.9e+00
8.8e-01
5.4e-01
cases:39.51%
controls:34.38%
cases:45.68%
controls:26.54%
cases:40.12%
controls:6.54%
—
—
cases:31.06%
controls:6.38%
cases:51.33%
controls:30.51%
cases:72.66%
controls:60.76%
64
557
98
1063
74
430
88
1190
65
106
97
1514
—
50
103
111
1512
77
486
73
1107
93
844
35
545
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.2e-01
8.4e-01
2.3e+00
—
1.9e+00
8.7e-01
5.4e-01
cases:39.51%
controls:34.38%
cases:45.68%
controls:26.54%
cases:40.12%
controls:6.54%
—
—
cases:31.06%
controls:6.38%
cases:51.33%
controls:30.63%
cases:72.66%
controls:60.84%
64
557
98
1063
74
430
88
1190
65
106
97
1514
—
50
103
111
1512
77
488
73
1105
93
845
35
544
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
2.2e-01
8.2e-01
2.3e+00
—
1.9e+00
8.8e-01
5.4e-01
cases:39.51%
controls:34.32%
cases:45.06%
controls:26.54%
cases:40.12%
controls:6.54%
—
—
cases:31.06%
controls:6.38%
cases:51.33%
controls:30.38%
cases:72.66%
controls:60.76%
64
556
98
1064
73
430
89
1190
65
106
97
1514
—
50
103
111
1512
77
484
73
1109
93
844
35
545
MCH [Entitic mass]
28539-5 [3035941]
2.3e-01
8.2e-01
2.3e+00
—
1.9e+00
8.8e-01
5.5e-01
cases:39.51%
controls:34.26%
cases:45.06%
controls:26.48%
cases:40.12%
controls:6.54%
—
—
cases:31.06%
controls:6.38%
cases:51.33%
controls:30.51%
cases:72.66%
controls:60.62%
64
555
98
1065
73
429
89
1191
65
106
97
1514
—
50
103
111
1512
77
486
73
1107
93
842
35
547
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
3.4e-01
8.1e-01
2.3e+00
—
1.9e+00
9.0e-01
6.4e-01
cases:38.89%
controls:31.17%
cases:41.36%
controls:23.95%
cases:34.57%
controls:5.25%
—
—
cases:27.33%
controls:5.45%
cases:46.67%
controls:26.24%
cases:70.31%
controls:55.65%
63
505
99
1115
67
388
95
1232
56
85
106
1535
—
44
88
117
1527
70
418
80
1175
90
773
38
616
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
1.2e+00
1.8e+00
—
—
—
2.0e+00
2.1e+00
cases:5.56%
controls:1.73%
cases:6.17%
controls:1.11%
—
—
—
—
—
—
cases:9.33%
controls:1.38%
cases:21.09%
controls:3.24%
9
28
153
1592
10
18
152
1602
—
—
—
14
22
136
1571
27
45
101
1344
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
2.4e-01
7.6e-01
2.2e+00
—
1.9e+00
8.5e-01
5.5e-01
cases:24.69%
controls:20.43%
cases:28.40%
controls:15.68%
cases:26.54%
controls:3.70%
—
—
cases:21.74%
controls:4.09%
cases:34.00%
controls:18.08%
cases:52.34%
controls:38.73%
40
331
122
1289
46
254
116
1366
43
60
119
1560
—
35
66
126
1549
51
288
99
1305
67
538
61
851
Parathyrin.intact [Mass/volume] in Serum or Plasma
2731-8 [3000067]
1.8e+00
—
—
—
—
2.1e+00
1.7e+00
cases:6.17%
controls:1.11%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.50%
cases:6.25%
controls:1.15%
10
18
152
1602
—
—
—
—
6
8
144
1585
8
16
120
1373
CBC panel - Blood by Automated count
58410-2 [40761511]
3.1e-01
8.1e-01
2.0e+00
—
2.0e+00
7.3e-01
6.2e-01
cases:35.19%
controls:28.40%
cases:33.95%
controls:18.64%
cases:22.84%
controls:3.70%
—
—
cases:19.88%
controls:3.22%
cases:36.67%
controls:21.85%
cases:62.50%
controls:47.23%
57
460
105
1160
55
302
107
1318
37
60
125
1560
—
32
52
129
1563
55
348
95
1245
80
656
48
733
Ketones [Presence] in Urine by Test strip
2514-8 [3035350]
7.8e-01
8.9e-01
2.4e+00
—
2.2e+00
9.9e-01
6.4e-01
cases:14.20%
controls:7.04%
cases:9.88%
controls:4.32%
cases:5.56%
controls:0.56%
—
—
cases:4.97%
controls:0.56%
cases:13.33%
controls:5.40%
cases:29.69%
controls:18.21%
23
114
139
1506
16
70
146
1550
9
9
153
1611
—
8
9
153
1606
20
86
130
1507
38
253
90
1136
Nitrite [Presence] in Urine by Test strip
5802-4 [3021601]
8.0e-01
9.5e-01
2.4e+00
—
2.2e+00
9.7e-01
6.8e-01
cases:14.20%
controls:6.91%
cases:9.88%
controls:4.07%
cases:5.56%
controls:0.56%
—
—
cases:4.97%
controls:0.56%
cases:12.67%
controls:5.21%
cases:30.47%
controls:18.14%
23
112
139
1508
16
66
146
1554
9
9
153
1611
—
8
9
153
1606
19
83
131
1510
39
252
89
1137
Case Management Agency
251B00000X [38004193]
2.5e-01
4.1e-01
8.0e-01
3.7e+00
9.6e-01
6.5e-01
3.9e-01
cases:70.37%
controls:64.88%
cases:68.52%
controls:59.01%
cases:39.51%
controls:22.65%
cases:28.40%
controls:0.93%
cases:42.86%
controls:22.29%
cases:76.67%
controls:63.09%
cases:89.06%
controls:84.59%
114
1051
48
569
111
956
51
664
64
367
98
1253
46
15
116
1605
69
360
92
1255
115
1005
35
588
114
1175
14
214
Glucose [Presence] in Urine by Test strip
25428-4 [3009261]
7.4e-01
9.0e-01
2.4e+00
—
2.2e+00
9.2e-01
6.3e-01
cases:14.20%
controls:7.28%
cases:9.88%
controls:4.26%
cases:5.56%
controls:0.56%
—
—
cases:4.97%
controls:0.56%
cases:12.67%
controls:5.46%
cases:29.69%
controls:18.29%
23
118
139
1502
16
69
146
1551
9
9
153
1611
—
8
9
153
1606
19
87
131
1506
38
254
90
1135
Ultrasound examination of upper part of abdomen
JN1AE [2001305517]
1.5e+00
2.7e+00
—
—
—
—
2.8e+00
cases:3.70%
controls:0.86%
cases:4.32%
controls:0.31%
—
—
—
—
—
—
—
—
cases:11.72%
controls:0.79%
6
14
156
1606
7
5
155
1615
—
—
—
—
15
11
113
1378
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
1.6e+00
1.5e+00
—
—
—
2.1e+00
1.7e+00
cases:4.94%
controls:0.99%
cases:3.09%
controls:0.68%
—
—
—
—
—
—
cases:4.00%
controls:0.50%
cases:9.38%
controls:1.94%
8
16
154
1604
5
11
157
1609
—
—
—
6
8
144
1585
12
27
116
1362
Medical Oncology
90 [38004507]
2.5e-01
2.8e-01
—
—
2.2e+00
1.6e+00
1.5e+00
cases:3.70%
controls:2.90%
cases:3.09%
controls:2.35%
—
—
—
—
cases:4.97%
controls:0.56%
cases:14.00%
controls:3.08%
cases:17.97%
controls:4.54%
6
47
156
1573
5
38
157
1582
—
—
8
9
153
1606
21
49
129
1544
23
63
105
1326
prednisolone; oral, parenteral
H02AB06 [21602734]
7.3e-01
1.1e+00
—
—
2.3e+00
1.1e+00
9.2e-01
cases:18.52%
controls:9.88%
cases:12.96%
controls:4.81%
—
—
—
—
cases:7.45%
controls:0.80%
cases:14.00%
controls:5.15%
cases:25.00%
controls:11.74%
30
160
132
1460
21
78
141
1542
—
—
12
13
149
1602
21
82
129
1511
32
163
96
1226
Influenza virus A RNA [Presence] in Specimen by NAA with probe detection
34487-9 [3044938]
1.9e+00
1.9e+00
—
—
1.0e+50
1.9e+00
1.6e+00
cases:6.79%
controls:1.11%
cases:3.70%
controls:0.56%
—
—
—
—
cases:3.11%
controls:0.00%
cases:6.00%
controls:0.94%
cases:16.41%
controls:3.74%
11
18
151
1602
6
9
156
1611
—
—
5
0
156
1615
9
15
141
1578
21
52
107
1337
prednisolone
A07EA01 [21600653]
7.2e-01
1.1e+00
—
—
2.3e+00
1.1e+00
9.1e-01
cases:18.52%
controls:9.94%
cases:12.96%
controls:4.81%
—
—
—
—
cases:7.45%
controls:0.80%
cases:14.00%
controls:5.15%
cases:25.00%
controls:11.88%
30
161
132
1459
21
78
141
1542
—
—
12
13
149
1602
21
82
129
1511
32
165
96
1224
Folate [Moles/volume] in Red Blood Cells
14731-4 [3019309]
7.7e-01
2.2e+00
1.0e+50
—
—
1.9e+00
1.2e+00
cases:7.41%
controls:3.58%
cases:6.17%
controls:0.74%
cases:3.09%
controls:0.00%
—
—
—
—
cases:6.00%
controls:0.94%
cases:13.28%
controls:4.32%
12
58
150
1562
10
12
152
1608
5
0
157
1620
—
—
9
15
141
1578
17
60
111
1329
calcium (different salts in combination); oral
A12AA20 [21600872]
9.3e-01
8.2e-01
1.1e+00
—
1.9e+00
1.3e+00
1.2e+00
cases:16.05%
controls:7.04%
cases:12.96%
controls:6.17%
cases:5.56%
controls:1.91%
—
—
cases:6.21%
controls:0.99%
cases:20.00%
controls:6.40%
cases:23.44%
controls:8.71%
26
114
136
1506
21
100
141
1520
9
31
153
1589
—
10
16
151
1599
30
102
120
1491
30
121
98
1268
pH of Urine
2756-5 [3015736]
9.0e-01
9.1e-01
2.2e+00
—
2.2e+00
8.2e-01
4.1e-01
cases:13.58%
controls:5.99%
cases:8.02%
controls:3.40%
cases:3.70%
controls:0.43%
—
—
cases:3.73%
controls:0.43%
cases:8.67%
controls:4.02%
cases:20.31%
controls:14.47%
22
97
140
1523
13
55
149
1565
6
7
156
1613
—
6
7
155
1608
13
64
137
1529
26
201
102
1188
Extensive body CT
JN4BD [2001310899]
1.3e+00
—
—
1.0e+50
—
2.7e+00
2.6e+00
cases:3.70%
controls:0.99%
—
—
—
—
cases:4.94%
controls:0.00%
—
—
cases:6.00%
controls:0.44%
cases:12.50%
controls:1.08%
6
16
156
1604
—
—
8
0
154
1620
—
9
7
141
1586
16
15
112
1374
Phosphate [Moles/volume] in Serum or Plasma
14879-1 [3003458]
1.3e+00
1.1e+00
—
—
—
2.0e+00
1.8e+00
cases:7.41%
controls:2.10%
cases:4.32%
controls:1.42%
—
—
—
—
—
—
cases:10.00%
controls:1.44%
cases:16.41%
controls:3.10%
12
34
150
1586
7
23
155
1597
—
—
—
15
23
135
1570
21
43
107
1346
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
1.4e+00
1.2e+00
—
—
2.7e+00
1.6e+00
1.1e+00
cases:6.79%
controls:1.79%
cases:4.32%
controls:1.30%
—
—
—
—
cases:4.35%
controls:0.31%
cases:4.67%
controls:0.94%
cases:14.84%
controls:5.62%
11
29
151
1591
7
21
155
1599
—
—
7
5
154
1610
7
15
143
1578
19
78
109
1311
pH of Specimen
17433-4 [3019225]
1.4e+00
2.1e+00
—
—
—
1.6e+00
1.6e+00
cases:6.17%
controls:1.60%
cases:4.32%
controls:0.56%
—
—
—
—
—
—
cases:4.00%
controls:0.82%
cases:9.38%
controls:2.09%
10
26
152
1594
7
9
155
1611
—
—
—
6
13
144
1580
12
29
116
1360
Cathetrisation of vein
TPH04 [2001309597]
1.5e+00
7.9e-01
—
—
—
1.8e+00
1.6e+00
cases:9.26%
controls:2.22%
cases:3.09%
controls:1.42%
—
—
—
—
—
—
cases:5.33%
controls:0.88%
cases:14.84%
controls:3.24%
15
36
147
1584
5
23
157
1597
—
—
—
8
14
142
1579
19
45
109
1344
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
7.2e-01
1.6e+00
2.3e+00
—
2.3e+00
1.1e+00
7.0e-01
cases:9.26%
controls:4.75%
cases:12.96%
controls:3.02%
cases:3.09%
controls:0.31%
—
—
cases:3.73%
controls:0.37%
cases:10.00%
controls:3.64%
cases:21.09%
controls:11.74%
15
77
147
1543
21
49
141
1571
5
5
157
1615
—
6
6
155
1609
15
58
135
1535
27
163
101
1226
Other and unspecified abdominal pain
R10.4 [45568113]
4.6e-01
2.1e+00
—
1.0e+50
—
1.5e+00
1.2e+00
cases:8.64%
controls:5.62%
cases:9.88%
controls:1.36%
—
—
cases:3.70%
controls:0.00%
—
—
cases:7.33%
controls:1.69%
cases:14.84%
controls:4.82%
14
91
148
1529
16
22
146
1598
—
6
0
156
1620
—
11
27
139
1566
19
67
109
1322
Lambda light chains.free [Mass/volume] in Serum or Plasma
33944-0 [3047169]
—
—
1.0e+50
—
—
2.6e+00
2.2e+00
—
—
—
—
cases:6.79%
controls:0.00%
—
—
—
—
cases:4.00%
controls:0.31%
cases:6.25%
controls:0.72%
—
—
11
0
151
1620
—
—
6
5
144
1588
8
10
120
1379
Kappa light chains.free [Mass/volume] in Serum
36916-5 [3034860]
—
—
1.0e+50
—
—
2.6e+00
2.2e+00
—
—
—
—
cases:6.79%
controls:0.00%
—
—
—
—
cases:4.00%
controls:0.31%
cases:6.25%
controls:0.72%
—
—
11
0
151
1620
—
—
6
5
144
1588
8
10
120
1379
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.1e+00
2.2e+00
—
—
—
—
1.4e+00
cases:8.02%
controls:2.78%
cases:4.94%
controls:0.56%
—
—
—
—
—
—
—
—
cases:10.16%
controls:2.59%
13
45
149
1575
8
9
154
1611
—
—
—
—
13
36
115
1353
Pharmacy visit
OMOP4822462 [581458]
8.2e-01
1.3e+00
8.5e-01
1.7e+00
9.3e-01
6.7e-01
1.3e+00
cases:97.53%
controls:94.57%
cases:95.06%
controls:83.83%
cases:66.67%
controls:46.11%
cases:9.88%
controls:1.98%
cases:67.70%
controls:45.26%
cases:92.00%
controls:85.50%
cases:98.44%
controls:94.60%
158
1532
4
88
154
1358
8
262
108
747
54
873
16
32
146
1588
109
731
52
884
138
1362
12
231
126
1314
2
75
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
1.2e+00
1.3e+00
1.6e+00
1.0e+50
1.9e+00
1.2e+00
1.0e+00
cases:16.05%
controls:5.49%
cases:9.26%
controls:2.59%
cases:3.09%
controls:0.62%
cases:3.70%
controls:0.00%
cases:3.73%
controls:0.56%
cases:8.00%
controls:2.45%
cases:17.97%
controls:7.42%
26
89
136
1531
15
42
147
1578
5
10
157
1610
6
0
156
1620
6
9
155
1606
12
39
138
1554
23
103
105
1286
High resolution CT examination of lungs
GD1DD [2001303632]
2.3e+00
—
—
—
—
—
2.4e+00
cases:4.32%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.58%
7
7
155
1613
—
—
—
—
—
8
8
120
1381
Short blood count panel - Blood
55429-5 [40758558]
5.2e-01
1.1e+00
1.7e+00
—
2.0e+00
1.6e+00
1.2e+00
cases:6.79%
controls:4.14%
cases:7.41%
controls:2.72%
cases:3.09%
controls:0.56%
—
—
cases:3.73%
controls:0.50%
cases:11.33%
controls:2.64%
cases:20.31%
controls:7.34%
11
67
151
1553
12
44
150
1576
5
9
157
1611
—
6
8
155
1607
17
42
133
1551
26
102
102
1287
Emergency Room and Inpatient Visit
ERIP [262]
1.1e+00
1.4e+00
—
1.0e+50
—
1.3e+00
9.6e-01
cases:8.64%
controls:3.02%
cases:6.17%
controls:1.60%
—
—
cases:4.94%
controls:0.00%
—
—
cases:8.67%
controls:2.64%
cases:19.53%
controls:8.50%
14
49
148
1571
10
26
152
1594
—
8
0
154
1620
—
13
42
137
1551
25
118
103
1271
Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2865-4 [3015322]
2.0e+00
—
—
—
—
2.6e+00
2.1e+00
cases:3.09%
controls:0.43%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.31%
cases:5.47%
controls:0.72%
5
7
157
1613
—
—
—
—
6
5
144
1588
7
10
121
1379
Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis
51435-6 [3029713]
2.3e+00
—
—
—
—
2.6e+00
2.1e+00
cases:3.09%
controls:0.31%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.31%
cases:5.47%
controls:0.72%
5
5
157
1615
—
—
—
—
6
5
144
1588
7
10
121
1379
Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma
2742-5 [3034780]
1.2e+00
2.0e+00
—
—
—
1.9e+00
2.6e+00
cases:3.09%
controls:0.93%
cases:3.70%
controls:0.49%
—
—
—
—
—
—
cases:3.33%
controls:0.50%
cases:5.47%
controls:0.43%
5
15
157
1605
6
8
156
1612
—
—
—
5
8
145
1585
7
6
121
1383
Infiltration anesthesia
WX110 [2001310767]
5.8e-01
1.0e+00
1.2e+00
—
1.9e+00
9.8e-01
7.3e-01
cases:29.01%
controls:18.58%
cases:17.28%
controls:7.16%
cases:3.09%
controls:0.93%
—
—
cases:5.59%
controls:0.87%
cases:18.00%
controls:7.60%
cases:42.19%
controls:25.99%
47
301
115
1319
28
116
134
1504
5
15
157
1605
—
9
14
152
1601
27
121
123
1472
54
361
74
1028
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
2.0e+00
—
—
—
—
2.4e+00
2.2e+00
cases:3.09%
controls:0.43%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.38%
cases:6.25%
controls:0.72%
5
7
157
1613
—
—
—
—
6
6
144
1587
8
10
120
1379
Beta 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32731-2 [3043747]
—
—
—
—
—
2.4e+00
2.2e+00
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.38%
cases:6.25%
controls:0.72%
—
—
—
—
—
6
6
144
1587
8
10
120
1379
Alpha 2 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2868-8 [3005229]
2.0e+00
—
—
—
—
2.4e+00
2.2e+00
cases:3.09%
controls:0.43%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.38%
cases:6.25%
controls:0.72%
5
7
157
1613
—
—
—
—
6
6
144
1587
8
10
120
1379
Gamma globulin [Mass/volume] in Serum or Plasma by Electrophoresis
2874-6 [3023465]
2.0e+00
—
—
—
—
2.4e+00
2.2e+00
cases:3.09%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.31%
cases:5.47%
controls:0.65%
5
7
157
1613
—
—
—
—
5
5
145
1588
7
9
121
1380
aPTT in Platelet poor plasma by Coagulation assay
14979-9 [3018677]
1.0e+00
1.6e+00
—
—
—
2.8e+00
1.8e+00
cases:5.56%
controls:2.10%
cases:3.09%
controls:0.62%
—
—
—
—
—
—
cases:10.00%
controls:0.69%
cases:17.19%
controls:3.31%
9
34
153
1586
5
10
157
1610
—
—
—
15
11
135
1582
22
46
106
1343
pantoprazole; oral, parenteral
A02BC02 [21600097]
4.3e-01
1.1e+00
1.2e+00
—
1.4e+00
1.2e+00
8.2e-01
cases:24.07%
controls:17.04%
cases:22.22%
controls:8.83%
cases:6.17%
controls:1.98%
—
—
cases:7.45%
controls:1.98%
cases:28.67%
controls:10.48%
cases:39.84%
controls:22.53%
39
276
123
1344
36
143
126
1477
10
32
152
1588
—
12
32
149
1583
43
167
107
1426
51
313
77
1076
12 lead EKG panel
34534-8 [3044889]
2.2e-01
2.6e-01
1.5e+00
—
2.0e+00
8.7e-01
3.1e-01
cases:17.90%
controls:14.94%
cases:11.11%
controls:8.77%
cases:5.56%
controls:1.23%
—
—
cases:6.21%
controls:0.87%
cases:19.33%
controls:9.17%
cases:31.25%
controls:24.91%
29
242
133
1378
18
142
144
1478
9
20
153
1600
—
10
14
151
1601
29
146
121
1447
40
346
88
1043
Insertion of central venous catheter through external or internal jugular vein
TPH15 [2001309600]
2.0e+00
-1.0e+50
—
—
—
—
2.4e+00
cases:4.32%
controls:0.62%
cases:0.00%
controls:0.43%
—
—
—
—
—
—
—
—
cases:3.91%
controls:0.36%
7
10
155
1610
0
7
162
1613
—
—
—
—
5
5
123
1384
Gas panel - Capillary blood
24337-8 [3022313]
2.2e+00
—
—
—
—
—
2.1e+00
cases:3.70%
controls:0.43%
—
—
—
—
—
—
—
—
—
—
cases:7.03%
controls:0.94%
6
7
156
1613
—
—
—
—
—
9
13
119
1376
Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection
54067-4 [3051552]
1.2e+00
—
—
—
—
2.4e+00
1.8e+00
cases:3.09%
controls:0.99%
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.44%
cases:7.03%
controls:1.22%
5
16
157
1604
—
—
—
—
7
7
143
1586
9
17
119
1372
Nephrology
39 [38004479]
2.2e+00
1.9e+00
—
—
—
1.9e+00
1.4e+00
cases:4.94%
controls:0.56%
cases:3.09%
controls:0.49%
—
—
—
—
—
—
cases:4.67%
controls:0.69%
cases:4.69%
controls:1.15%
8
9
154
1611
5
8
157
1612
—
—
—
7
11
143
1582
6
16
122
1373
Immunohistochemistry procedure
117617002 [4035726]
1.3e+00
—
—
—
—
2.4e+00
1.7e+00
cases:4.32%
controls:1.23%
—
—
—
—
—
—
—
—
cases:6.00%
controls:0.56%
cases:9.38%
controls:1.80%
7
20
155
1600
—
—
—
—
9
9
141
1584
12
25
116
1364
ciclesonide; inhalant
R03BA08 [21603291]
1.2e+00
2.2e+00
—
—
—
1.8e+00
2.0e+00
cases:3.09%
controls:0.93%
cases:3.70%
controls:0.43%
—
—
—
—
—
—
cases:4.00%
controls:0.69%
cases:9.38%
controls:1.44%
5
15
157
1605
6
7
156
1613
—
—
—
6
11
144
1582
12
20
116
1369
ciclesonide; nasal
R01AD13 [43534836]
1.2e+00
2.2e+00
—
—
—
1.8e+00
2.0e+00
cases:3.09%
controls:0.93%
cases:3.70%
controls:0.43%
—
—
—
—
—
—
cases:4.00%
controls:0.69%
cases:9.38%
controls:1.44%
5
15
157
1605
6
7
156
1613
—
—
—
6
11
144
1582
12
20
116
1369
tinzaparin; parenteral
B01AB10 [21600981]
—
—
—
—
—
2.1e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:5.33%
controls:0.69%
cases:8.59%
controls:1.22%
—
—
—
—
—
8
11
142
1582
11
17
117
1372
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
1.3e+00
1.2e+00
—
—
—
1.5e+00
1.2e+00
cases:11.11%
controls:3.21%
cases:5.56%
controls:1.67%
—
—
—
—
—
—
cases:10.00%
controls:2.51%
cases:12.50%
controls:4.32%
18
52
144
1568
9
27
153
1593
—
—
—
15
40
135
1553
16
60
112
1329
Body CT examination
JN4AD [2001310897]
—
—
—
—
—
1.9e+00
2.0e+00
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.69%
cases:10.94%
controls:1.66%
—
—
—
—
—
7
11
143
1582
14
23
114
1366
Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection
40987-0 [3043924]
2.4e+00
—
—
—
—
1.8e+00
1.5e+00
cases:6.17%
controls:0.62%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.56%
cases:11.72%
controls:2.74%
10
10
152
1610
—
—
—
—
5
9
145
1584
15
38
113
1351
Influenza virus B RNA [Presence] in Specimen by NAA with probe detection
40982-1 [3038288]
2.4e+00
—
—
—
—
1.7e+00
1.5e+00
cases:6.17%
controls:0.62%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.63%
cases:11.72%
controls:2.74%
10
10
152
1610
—
—
—
—
5
10
145
1583
15
38
113
1351
carvedilol; oral
C07AG02 [21601700]
—
—
—
—
—
1.8e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:4.67%
controls:0.82%
cases:5.47%
controls:0.72%
—
—
—
—
—
7
13
143
1580
7
10
121
1379
Gas panel - Venous blood
24339-4 [3000991]
1.7e+00
—
—
—
—
2.0e+00
1.9e+00
cases:4.32%
controls:0.80%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.56%
cases:8.59%
controls:1.44%
7
13
155
1607
—
—
—
—
6
9
144
1584
11
20
117
1369
Hemoglobin A1c/Hemoglobin.total in Blood
4548-4 [3004410]
6.1e-01
7.6e-01
1.7e+00
—
1.0e+00
8.1e-01
4.0e-01
cases:30.86%
controls:19.51%
cases:24.07%
controls:12.96%
cases:9.26%
controls:1.91%
—
—
cases:4.97%
controls:1.80%
cases:28.67%
controls:15.13%
cases:50.78%
controls:40.82%
50
316
112
1304
39
210
123
1410
15
31
147
1589
—
8
29
153
1586
43
241
107
1352
65
567
63
822
potassium chloride; oral
A12BA01 [21600877]
1.9e+00
—
—
—
—
1.6e+00
2.0e+00
cases:4.94%
controls:0.80%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.82%
cases:12.50%
controls:1.94%
8
13
154
1607
—
—
—
—
6
13
144
1580
16
27
112
1362
Epithelial cells [#/volume] in Urine
30383-4 [3000850]
1.2e+00
9.0e-01
—
1.0e+50
—
1.3e+00
1.3e+00
cases:8.64%
controls:2.84%
cases:3.70%
controls:1.54%
—
—
cases:3.09%
controls:0.00%
—
—
cases:7.33%
controls:2.01%
cases:17.19%
controls:5.40%
14
46
148
1574
6
25
156
1595
—
5
0
157
1620
—
11
32
139
1561
22
75
106
1314
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
1.1e+00
—
—
—
—
2.1e+00
1.7e+00
cases:5.56%
controls:1.85%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.50%
cases:10.94%
controls:2.23%
9
30
153
1590
—
—
—
—
6
8
144
1585
14
31
114
1358
Bacteria identified in Isolate by Culture
43409-2 [3042936]
8.6e-01
1.5e+00
—
—
1.0e+50
2.0e+00
1.7e+00
cases:3.70%
controls:1.60%
cases:3.09%
controls:0.68%
—
—
—
—
cases:3.11%
controls:0.00%
cases:6.00%
controls:0.82%
cases:14.06%
controls:2.81%
6
26
156
1594
5
11
157
1609
—
—
5
0
156
1615
9
13
141
1580
18
39
110
1350
propranolol; oral, parenteral
C07AA05 [21601670]
1.0e+00
1.1e+00
—
—
—
1.5e+00
1.2e+00
cases:9.88%
controls:3.77%
cases:6.17%
controls:2.16%
—
—
—
—
—
—
cases:10.00%
controls:2.32%
cases:13.28%
controls:4.39%
16
61
146
1559
10
35
152
1585
—
—
—
15
37
135
1556
17
61
111
1328
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
3.6e-01
8.5e-01
2.3e+00
—
—
1.3e+00
8.0e-01
cases:8.02%
controls:5.74%
cases:4.94%
controls:2.16%
cases:3.70%
controls:0.37%
—
—
—
—
cases:10.00%
controls:2.82%
cases:16.41%
controls:8.14%
13
93
149
1527
8
35
154
1585
6
6
156
1614
—
—
15
45
135
1548
21
113
107
1276
Essential (primary) hypertension
I10 [45591453]
6.6e-01
9.1e-01
1.2e+00
1.0e+50
2.0e+00
6.5e-01
6.0e-01
cases:25.31%
controls:14.94%
cases:16.67%
controls:7.47%
cases:4.32%
controls:1.30%
cases:8.02%
controls:0.00%
cases:6.83%
controls:0.99%
cases:14.67%
controls:8.22%
cases:35.16%
controls:22.89%
41
242
121
1378
27
121
135
1499
7
21
155
1599
13
0
149
1620
11
16
150
1599
22
131
128
1462
45
318
83
1071
ECG with 12 standard connections
XF400 [2001303368]
1.8e+00
—
—
—
—
—
1.7e+00
cases:5.56%
controls:0.99%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.15%
9
16
153
1604
—
—
—
—
—
8
16
120
1373
Base excess.100% oxygenated [Moles/volume] standard in Capillary blood by calculation
72720-6 [43055554]
2.0e+00
—
—
—
—
—
1.5e+00
cases:4.32%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:1.80%
7
10
155
1610
—
—
—
—
—
10
25
118
1364
pH of Capillary blood
2745-8 [3009343]
2.0e+00
—
—
—
—
—
1.5e+00
cases:4.32%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:1.80%
7
10
155
1610
—
—
—
—
—
10
25
118
1364
EKG study
11524-6 [3013512]
7.9e-01
1.4e+00
—
—
1.9e+00
1.1e+00
9.7e-01
cases:9.88%
controls:4.75%
cases:8.02%
controls:2.04%
—
—
—
—
cases:3.11%
controls:0.50%
cases:9.33%
controls:3.39%
cases:21.09%
controls:9.22%
16
77
146
1543
13
33
149
1587
—
—
5
8
156
1607
14
54
136
1539
27
128
101
1261
aciclovir; oral, parenteral
J05AB01 [21603131]
—
2.0e+00
—
—
—
—
1.4e+00
—
—
cases:4.94%
controls:0.68%
—
—
—
—
—
—
—
—
cases:8.59%
controls:2.16%
—
8
11
154
1609
—
—
—
—
11
30
117
1359
bisoprolol; oral
C07AB07 [21601689]
1.0e+00
9.9e-01
9.5e-01
—
7.0e-01
7.6e-01
7.1e-01
cases:31.48%
controls:14.44%
cases:29.63%
controls:13.52%
cases:8.64%
controls:3.52%
—
—
cases:6.83%
controls:3.53%
cases:26.00%
controls:14.06%
cases:31.25%
controls:18.21%
51
234
111
1386
48
219
114
1401
14
57
148
1563
—
11
57
150
1558
39
224
111
1369
40
253
88
1136
General anesthesia, balanced
WX408 [2001310808]
4.3e-01
—
—
—
—
2.0e+00
1.4e+00
cases:6.79%
controls:4.51%
—
—
—
—
—
—
—
—
cases:6.00%
controls:0.82%
cases:8.59%
controls:2.23%
11
73
151
1547
—
—
—
—
9
13
141
1580
11
31
117
1358
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
2.0e+00
—
—
—
—
—
1.5e+00
cases:4.32%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:1.94%
7
10
155
1610
—
—
—
—
—
10
27
118
1362
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
1.5e-01
5.9e-01
1.8e+00
—
1.5e+00
5.0e-01
1.6e-01
cases:28.40%
controls:25.49%
cases:29.63%
controls:18.95%
cases:22.22%
controls:4.32%
—
—
cases:17.39%
controls:4.46%
cases:30.67%
controls:21.16%
cases:50.78%
controls:46.72%
46
413
116
1207
48
307
114
1313
36
70
126
1550
—
28
72
133
1543
46
337
104
1256
65
649
63
740
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
1.6e+00
—
—
—
—
—
1.7e+00
cases:6.17%
controls:1.30%
—
—
—
—
—
—
—
—
—
—
cases:12.50%
controls:2.52%
10
21
152
1599
—
—
—
—
—
16
35
112
1354
Heart failure, unspecified
I50.9 [45576879]
1.5e+00
1.8e+00
—
1.0e+50
—
1.2e+00
6.1e-01
cases:6.17%
controls:1.48%
cases:5.56%
controls:0.93%
—
—
cases:3.09%
controls:0.00%
—
—
cases:3.33%
controls:1.00%
cases:3.91%
controls:2.16%
10
24
152
1596
9
15
153
1605
—
5
0
157
1620
—
5
16
145
1577
5
30
123
1359
roxithromycin; oral
J01FA06 [21602974]
4.9e-01
1.9e+00
—
—
—
1.0e+00
1.4e+00
cases:6.17%
controls:3.89%
cases:4.32%
controls:0.68%
—
—
—
—
—
—
cases:3.33%
controls:1.19%
cases:8.59%
controls:2.30%
10
63
152
1557
7
11
155
1609
—
—
—
5
19
145
1574
11
32
117
1357
Antithrombin actual/normal in Platelet poor plasma by Chromogenic method
27811-9 [3000515]
1.9e+00
—
—
—
—
—
3.3e+00
cases:3.09%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:8.59%
controls:0.36%
5
8
157
1612
—
—
—
—
—
11
5
117
1384
Thrombin time
3243-3 [3036489]
—
—
—
—
—
—
3.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.59%
controls:0.36%
—
—
—
—
—
—
11
5
117
1384
Coloscopy
UJF32 [2001305029]
8.3e-01
1.9e+00
—
—
—
1.2e+00
1.3e+00
cases:8.64%
controls:3.95%
cases:6.17%
controls:0.93%
—
—
—
—
—
—
cases:4.00%
controls:1.19%
cases:12.50%
controls:3.74%
14
64
148
1556
10
15
152
1605
—
—
—
6
19
144
1574
16
52
112
1337
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
3.0e-01
5.7e-01
1.7e+00
—
1.6e+00
4.9e-01
5.1e-01
cases:30.25%
controls:24.38%
cases:21.60%
controls:13.46%
cases:8.64%
controls:1.73%
—
—
cases:6.21%
controls:1.36%
cases:23.33%
controls:15.69%
cases:56.25%
controls:43.56%
49
395
113
1225
35
218
127
1402
14
28
148
1592
—
10
22
151
1593
35
250
115
1343
72
605
56
784
Bacterial infection, unspecified
A49.9 [45590816]
1.2e+00
—
—
1.0e+50
—
3.2e+00
1.4e+00
cases:3.70%
controls:1.11%
—
—
—
—
cases:3.09%
controls:0.00%
—
—
cases:7.33%
controls:0.31%
cases:6.25%
controls:1.66%
6
18
156
1602
—
—
5
0
157
1620
—
11
5
139
1588
8
23
120
1366
Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay
3255-7 [3016407]
—
—
—
—
—
—
3.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.28%
controls:0.65%
—
—
—
—
—
—
17
9
111
1380
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
8.4e-01
1.2e+00
—
—
—
1.8e+00
1.4e+00
cases:8.02%
controls:3.64%
cases:4.94%
controls:1.54%
—
—
—
—
—
—
cases:8.67%
controls:1.57%
cases:14.84%
controls:4.25%
13
59
149
1561
8
25
154
1595
—
—
—
13
25
137
1568
19
59
109
1330
Ammonium ion [Moles/volume] in Plasma
1845-7 [3023183]
—
—
—
—
—
—
3.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.16%
controls:0.50%
—
—
—
—
—
—
13
7
115
1382
Morphology [Interpretation] in Bone marrow Narrative
51628-6 [3042111]
—
—
—
—
1.0e+50
1.0e+50
3.1e+00
—
—
—
—
—
—
—
—
cases:4.97%
controls:0.00%
cases:9.33%
controls:0.00%
cases:8.59%
controls:0.43%
—
—
—
—
8
0
153
1615
14
0
136
1593
11
6
117
1383
Pulmonary Disease
29 [38004472]
8.0e-01
7.3e-01
—
—
1.7e+00
1.0e+00
1.2e+00
cases:17.28%
controls:8.58%
cases:7.41%
controls:3.70%
—
—
—
—
cases:4.35%
controls:0.80%
cases:11.33%
controls:4.33%
cases:24.22%
controls:8.86%
28
139
134
1481
12
60
150
1560
—
—
7
13
154
1602
17
69
133
1524
31
123
97
1266
Medical doctor
Z2221 [2001311556]
5.7e-01
1.5e+00
—
—
—
1.5e+00
8.4e-01
cases:8.02%
controls:4.69%
cases:7.41%
controls:1.73%
—
—
—
—
—
—
cases:7.33%
controls:1.76%
cases:7.81%
controls:3.53%
13
76
149
1544
12
28
150
1592
—
—
—
11
28
139
1565
10
49
118
1340
Physiotherapy
R4110 [2001310233]
1.0e+00
5.6e-01
—
—
—
1.9e+00
1.0e+00
cases:11.11%
controls:4.26%
cases:3.09%
controls:1.79%
—
—
—
—
—
—
cases:8.00%
controls:1.32%
cases:11.72%
controls:4.61%
18
69
144
1551
5
29
157
1591
—
—
—
12
21
138
1572
15
64
113
1325
Osmolality of Urine
2695-5 [3026782]
9.6e-01
8.2e-01
—
1.0e+50
—
1.6e+00
1.2e+00
cases:7.41%
controls:2.96%
cases:3.70%
controls:1.67%
—
—
cases:3.09%
controls:0.00%
—
—
cases:8.00%
controls:1.69%
cases:13.28%
controls:4.25%
12
48
150
1572
6
27
156
1593
—
5
0
157
1620
—
12
27
138
1566
17
59
111
1330
sitagliptin; oral
A10BH01 [21600784]
9.8e-01
1.4e+00
—
—
—
1.4e+00
1.1e+00
cases:5.56%
controls:2.16%
cases:6.17%
controls:1.60%
—
—
—
—
—
—
cases:6.67%
controls:1.69%
cases:8.59%
controls:2.95%
9
35
153
1585
10
26
152
1594
—
—
—
10
27
140
1566
11
41
117
1348
metformin; oral
A10BA02 [21600747]
9.7e-01
9.5e-01
8.9e-01
—
7.9e-01
8.6e-01
4.4e-01
cases:22.84%
controls:10.06%
cases:21.60%
controls:9.63%
cases:8.02%
controls:3.46%
—
—
cases:6.21%
controls:2.91%
cases:20.67%
controls:9.92%
cases:18.75%
controls:12.89%
37
163
125
1457
35
156
127
1464
13
56
149
1564
—
10
47
151
1568
31
158
119
1435
24
179
104
1210
Thorax CT examination
GD1AD [2001303618]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.36%
—
—
—
—
—
—
7
5
121
1384
Reticulocyte production index
31111-8 [3000012]
—
—
—
—
1.0e+50
—
2.8e+00
—
—
—
—
—
—
—
—
cases:3.11%
controls:0.00%
—
—
cases:5.47%
controls:0.36%
—
—
—
—
5
0
156
1615
—
7
5
121
1384
CD4 cells/Lymphocytes in Specimen
80223-1 [21494815]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.36%
—
—
—
—
—
—
7
5
121
1384
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
—
—
—
—
—
—
2.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.38%
controls:0.65%
—
—
—
—
—
—
12
9
116
1380
cefalexin; oral
J01DB01 [21602870]
5.1e-01
3.8e-01
1.0e+00
—
1.7e+00
6.6e-01
1.1e+00
cases:38.89%
controls:27.72%
cases:13.58%
controls:9.69%
cases:3.09%
controls:1.11%
—
—
cases:4.97%
controls:0.99%
cases:17.33%
controls:9.79%
cases:51.56%
controls:26.42%
63
449
99
1171
22
157
140
1463
5
18
157
1602
—
8
16
153
1599
26
156
124
1437
66
367
62
1022
Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay
3209-4 [3019250]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.03%
controls:0.50%
—
—
—
—
—
—
9
7
119
1382
Scheduled procedure
ZXD10 [2001311387]
-1.1e-02
6.1e-01
—
—
—
1.6e+00
1.1e+00
cases:6.17%
controls:6.23%
cases:3.70%
controls:2.04%
—
—
—
—
—
—
cases:6.00%
controls:1.26%
cases:10.94%
controls:4.03%
10
101
152
1519
6
33
156
1587
—
—
—
9
20
141
1573
14
56
114
1333
Extensive abdominal CT
JN3BD [2001305556]
—
—
—
—
—
—
2.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:0.58%
—
—
—
—
—
—
10
8
118
1381
Smooth muscle Ab [Titer] in Serum
8095-2 [3007566]
1.6e+00
—
—
—
—
—
2.7e+00
cases:3.09%
controls:0.62%
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:0.58%
5
10
157
1610
—
—
—
—
—
10
8
118
1381
Chest pain, unspecified
R07.4 [45558450]
1.0e+00
1.6e+00
—
—
—
1.2e+00
5.5e-01
cases:9.26%
controls:3.46%
cases:5.56%
controls:1.17%
—
—
—
—
—
—
cases:3.33%
controls:1.07%
cases:7.81%
controls:4.68%
15
56
147
1564
9
19
153
1601
—
—
—
5
17
145
1576
10
65
118
1324
Inpatient Visit
IP [9201]
4.5e-01
8.4e-01
—
—
—
1.6e+00
1.0e+00
cases:7.41%
controls:4.88%
cases:5.56%
controls:2.47%
—
—
—
—
—
—
cases:10.67%
controls:2.39%
cases:18.75%
controls:7.49%
12
79
150
1541
9
40
153
1580
—
—
—
16
38
134
1555
24
104
104
1285
Clinical & Laboratory Dermatological Immunology Physician
207NI0002X [38003841]
8.3e-01
1.1e+00
—
—
1.7e+00
1.4e+00
1.3e+00
cases:12.35%
controls:5.80%
cases:6.79%
controls:2.47%
—
—
—
—
cases:3.11%
controls:0.56%
cases:8.67%
controls:2.39%
cases:18.75%
controls:6.05%
20
94
142
1526
11
40
151
1580
—
—
5
9
156
1606
13
38
137
1555
24
84
104
1305
Immunoglobulin light chains.free panel - Serum
57778-3 [40760888]
—
—
1.0e+50
—
—
—
2.6e+00
—
—
—
—
cases:4.94%
controls:0.00%
—
—
—
—
—
—
cases:4.69%
controls:0.36%
—
—
8
0
154
1620
—
—
—
6
5
122
1384
Diabetes non-insulin dependent
T90 [2002001131]
1.3e+00
1.3e+00
—
—
—
5.0e-01
7.4e-01
cases:16.05%
controls:5.19%
cases:10.49%
controls:3.02%
—
—
—
—
—
—
cases:6.67%
controls:4.14%
cases:17.19%
controls:9.00%
26
84
136
1536
17
49
145
1571
—
—
—
10
66
140
1527
22
125
106
1264
Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection
38917-1 [3042194]
—
—
—
—
—
—
2.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.50%
—
—
—
—
—
—
8
7
120
1382
Kappa light chains/Lambda light chains [Mass Ratio] in Serum
15189-4 [3007778]
—
—
1.0e+50
—
—
—
2.6e+00
—
—
—
—
cases:6.79%
controls:0.00%
—
—
—
—
—
—
cases:6.25%
controls:0.50%
—
—
11
0
151
1620
—
—
—
8
7
120
1382
Treatment plan or consultation
WZC00 [2001310885]
8.4e-01
—
—
—
—
1.5e+00
1.1e+00
cases:11.11%
controls:5.12%
—
—
—
—
—
—
—
—
cases:8.67%
controls:2.07%
cases:16.41%
controls:6.34%
18
83
144
1537
—
—
—
—
13
33
137
1560
21
88
107
1301
Office Visit
OMOP4822458 [581477]
5.2e-01
1.6e+00
—
—
—
6.9e-01
9.6e-01
cases:14.20%
controls:8.95%
cases:11.11%
controls:2.53%
—
—
—
—
—
—
cases:6.67%
controls:3.45%
cases:15.63%
controls:6.62%
23
145
139
1475
18
41
144
1579
—
—
—
10
55
140
1538
20
92
108
1297
Alpha 1 antitrypsin [Mass/volume] in Serum or Plasma
1825-9 [3026285]
2.5e+00
—
—
—
—
—
—
cases:3.70%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
156
1615
—
—
—
—
—
—
Other obesity
E66.8 [45533036]
2.5e+00
—
—
—
—
—
—
cases:3.70%
controls:0.31%
—
—
—
—
—
—
—
—
—
—
—
—
6
5
156
1615
—
—
—
—
—
—
Epstein Barr virus Ab [Presence] in Serum
49178-7 [3048929]
2.5e+00
—
1.0e+50
—
1.0e+50
—
—
cases:4.94%
controls:0.43%
—
—
cases:3.09%
controls:0.00%
—
—
cases:3.11%
controls:0.00%
—
—
—
—
8
7
154
1613
—
5
0
157
1620
—
5
0
156
1615
—
—
Oncology Clinic/Center
261QX0200X [38004268]
-2.0e-01
6.7e-01
—
—
—
1.4e+00
1.0e+00
cases:4.32%
controls:5.25%
cases:3.09%
controls:1.60%
—
—
—
—
—
—
cases:7.33%
controls:1.82%
cases:11.72%
controls:4.54%
7
85
155
1535
5
26
157
1594
—
—
—
11
29
139
1564
15
63
113
1326
Mitochondria Ab [Titer] in Serum
20483-4 [3034770]
1.7e+00
—
—
—
—
—
2.4e+00
cases:3.09%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
cases:7.03%
controls:0.65%
5
9
157
1611
—
—
—
—
—
9
9
119
1380
Cytomegalovirus DNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
72493-0 [43055120]
—
—
—
—
1.0e+50
—
2.4e+00
—
—
—
—
—
—
—
—
cases:4.35%
controls:0.00%
—
—
cases:6.25%
controls:0.58%
—
—
—
—
7
0
154
1615
—
8
8
120
1381
Intravenous administration of medicine
SPAT1255 [2001700356]
—
-1.0e+50
—
—
—
—
2.4e+00
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.50%
—
0
6
162
1614
—
—
—
—
7
7
121
1382
Adenovirus DNA [Identifier] in Specimen by NAA with probe detection
40976-3 [3040853]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.50%
—
—
—
—
—
—
7
7
121
1382
Immunofixation for Serum or Plasma
25700-6 [3037756]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.69%
controls:0.43%
—
—
—
—
—
—
6
6
122
1383
Complement C3 [Mass/volume] in Serum or Plasma
4485-9 [3000620]
1.9e+00
—
—
—
—
—
2.4e+00
cases:3.09%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:4.69%
controls:0.43%
5
8
157
1612
—
—
—
—
—
6
6
122
1383
Initiation and monitoring of IV fluid therapy
SPAT1083 [2001700184]
—
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.69%
controls:0.43%
—
—
—
—
—
—
6
6
122
1383
Complement C4 [Mass/volume] in Serum or Plasma
4498-2 [3017766]
1.9e+00
—
—
—
—
—
2.4e+00
cases:3.09%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:4.69%
controls:0.43%
5
8
157
1612
—
—
—
—
—
6
6
122
1383
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
6.4e-01
7.3e-01
1.8e+00
—
1.1e+00
5.3e-01
4.4e-01
cases:26.54%
controls:15.99%
cases:17.28%
controls:9.14%
cases:9.26%
controls:1.73%
—
—
cases:4.35%
controls:1.42%
cases:15.33%
controls:9.67%
cases:39.06%
controls:29.23%
43
259
119
1361
28
148
134
1472
15
28
147
1592
—
7
23
154
1592
23
154
127
1439
50
406
78
983
Treponema pallidum Ab [Presence] in Serum
22587-0 [3019832]
7.5e-01
—
—
—
—
2.4e+00
—
cases:3.70%
controls:1.79%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.31%
—
—
6
29
156
1591
—
—
—
—
5
5
145
1588
—
Cystatin C [Mass/volume] in Serum or Plasma
33863-2 [3030366]
1.9e+00
—
—
—
—
2.4e+00
1.8e+00
cases:3.70%
controls:0.56%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.31%
cases:4.69%
controls:0.79%
6
9
156
1611
—
—
—
—
5
5
145
1588
6
11
122
1378
Haptoglobin [Mass/volume] in Serum or Plasma
4542-7 [3012336]
2.4e+00
—
—
—
—
—
—
cases:5.56%
controls:0.56%
—
—
—
—
—
—
—
—
—
—
—
—
9
9
153
1611
—
—
—
—
—
—
metronidazole; oral, rectal
P01AB01 [21604857]
9.7e-01
1.4e+00
—
—
—
—
2.6e-01
cases:14.20%
controls:5.93%
cases:7.41%
controls:1.98%
—
—
—
—
—
—
—
—
cases:8.59%
controls:6.77%
23
96
139
1524
12
32
150
1588
—
—
—
—
11
94
117
1295
General Practice
1 [38004446]
5.7e-01
8.1e-01
1.6e+00
—
2.3e+00
5.9e-01
5.0e-01
cases:18.52%
controls:11.36%
cases:9.88%
controls:4.63%
cases:3.09%
controls:0.62%
—
—
cases:4.35%
controls:0.43%
cases:10.00%
controls:5.78%
cases:24.22%
controls:16.20%
30
184
132
1436
16
75
146
1545
5
10
157
1610
—
7
7
154
1608
15
92
135
1501
31
225
97
1164
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
2.3e+00
—
—
—
—
—
—
cases:3.70%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
156
1614
—
—
—
—
—
—
Pain localized to upper abdomen
R10.1 [45568111]
9.8e-01
2.3e+00
—
—
—
2.1e+00
—
cases:4.32%
controls:1.67%
cases:3.70%
controls:0.37%
—
—
—
—
—
—
cases:3.33%
controls:0.44%
—
—
7
27
155
1593
6
6
156
1614
—
—
—
5
7
145
1586
—
Type 2 diabetes mellitus, with multiple complications
E11.7 [45561950]
2.3e+00
—
—
—
—
—
1.7e+00
cases:3.70%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:1.01%
6
6
156
1614
—
—
—
—
—
7
14
121
1375
Measurement of bone density from two or more locations with X-ray
NK6QA [2001308500]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.65%
—
—
—
—
—
—
8
9
120
1380
DNA double strand Ab [Units/volume] in Serum
5130-0 [3023420]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.58%
—
—
—
—
—
—
7
8
121
1381
Abdominal CT examination
JN3AD [2001305554]
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
cases:5.33%
controls:0.56%
—
—
—
—
—
—
—
8
9
142
1584
—
Fungus identified in Specimen by Culture
580-1 [3000494]
9.8e-01
—
—
—
—
2.2e+00
1.1e+00
cases:4.32%
controls:1.67%
—
—
—
—
—
—
—
—
cases:5.33%
controls:0.63%
cases:8.59%
controls:2.95%
7
27
155
1593
—
—
—
—
8
10
142
1583
11
41
117
1348
Oral Surgery
19 [38004464]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.65%
—
—
—
—
—
—
7
9
121
1380
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
3.6e-01
6.3e-01
6.6e-01
—
9.3e-01
8.9e-01
6.5e-01
cases:41.98%
controls:33.58%
cases:27.78%
controls:16.98%
cases:5.56%
controls:2.96%
—
—
cases:5.59%
controls:2.29%
cases:34.00%
controls:17.51%
cases:57.81%
controls:41.68%
68
544
94
1076
45
275
117
1345
9
48
153
1572
—
9
37
152
1578
51
279
99
1314
74
579
54
810
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.79%
—
—
—
—
—
—
8
11
120
1378
Base excess in Arterial blood by calculation
1925-7 [3003396]
1.5e+00
—
—
—
—
2.1e+00
8.9e-01
cases:4.94%
controls:1.17%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.50%
cases:7.03%
controls:3.02%
8
19
154
1601
—
—
—
—
6
8
144
1585
9
42
119
1347
folic acid
V04CX02 [715877]
—
1.7e+00
—
—
—
2.1e+00
1.0e+00
—
—
cases:3.09%
controls:0.56%
—
—
—
—
—
—
cases:5.33%
controls:0.69%
cases:5.47%
controls:2.02%
—
5
9
157
1611
—
—
—
8
11
142
1582
7
28
121
1361
folic acid; oral, parenteral
B03BB01 [21601129]
—
1.7e+00
—
—
—
2.1e+00
1.0e+00
—
—
cases:3.09%
controls:0.56%
—
—
—
—
—
—
cases:5.33%
controls:0.69%
cases:5.47%
controls:2.02%
—
5
9
157
1611
—
—
—
8
11
142
1582
7
28
121
1361
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
2.1e+00
—
—
—
—
—
2.1e+00
cases:3.09%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
cases:5.47%
controls:0.72%
5
6
157
1614
—
—
—
—
—
7
10
121
1379
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
7.1e-01
8.5e-01
—
—
2.0e+00
9.6e-01
5.1e-01
cases:11.73%
controls:6.11%
cases:8.02%
controls:3.58%
—
—
—
—
cases:3.73%
controls:0.50%
cases:10.00%
controls:4.08%
cases:21.88%
controls:14.40%
19
99
143
1521
13
58
149
1562
—
—
6
8
155
1607
15
65
135
1528
28
200
100
1189
Urinary tract ultrasound examination
KH1AE [2001306329]
2.0e+00
—
—
—
—
—
—
cases:3.70%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
156
1612
—
—
—
—
—
—
ferrous glycine sulfate; oral
B03AA01 [21601080]
2.0e+00
—
—
—
—
2.1e+00
1.4e+00
cases:3.70%
controls:0.49%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.44%
cases:4.69%
controls:1.15%
6
8
156
1612
—
—
—
—
5
7
145
1586
6
16
122
1373
Cardiology
6 [38004451]
8.1e-01
7.5e-01
1.4e+00
—
1.2e+00
1.2e+00
5.6e-01
cases:18.52%
controls:9.20%
cases:10.49%
controls:5.25%
cases:3.09%
controls:0.80%
—
—
cases:3.11%
controls:0.93%
cases:15.33%
controls:5.15%
cases:17.97%
controls:11.16%
30
149
132
1471
17
85
145
1535
5
13
157
1607
—
5
15
156
1600
23
82
127
1511
23
155
105
1234
Teaching
WZC30 [2001310891]
—
—
—
—
—
2.0e+00
8.9e-01
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.56%
cases:7.03%
controls:3.02%
—
—
—
—
—
6
9
144
1584
9
42
119
1347
oxycodone and naloxone; oral
N02AA55 [21604265]
—
—
—
—
—
2.0e+00
8.9e-01
—
—
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.56%
cases:7.03%
controls:3.02%
—
—
—
—
—
6
9
144
1584
9
42
119
1347
Functional capacity evaluation
443351003 [40481051]
6.3e-01
—
—
—
—
2.0e+00
6.2e-01
cases:4.32%
controls:2.35%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.56%
cases:5.47%
controls:3.02%
7
38
155
1582
—
—
—
—
6
9
144
1584
7
42
121
1347
valaciclovir; oral
J05AB11 [21603137]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.94%
controls:1.66%
—
—
—
—
—
—
14
23
114
1366
Remote contact by phone
ZYC01 [2001311579]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.94%
—
—
—
—
—
—
8
13
120
1376
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
8.4e-01
1.9e+00
2.1e+00
—
—
1.3e+00
4.6e-01
cases:7.41%
controls:3.33%
cases:6.79%
controls:1.05%
cases:3.09%
controls:0.37%
—
—
—
—
cases:4.00%
controls:1.07%
cases:8.59%
controls:5.62%
12
54
150
1566
11
17
151
1603
5
6
157
1614
—
—
6
17
144
1576
11
78
117
1311
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
9.4e-01
8.5e-01
—
—
—
9.8e-01
6.3e-01
cases:12.96%
controls:5.49%
cases:8.64%
controls:3.89%
—
—
—
—
—
—
cases:11.33%
controls:4.58%
cases:21.09%
controls:12.46%
21
89
141
1531
14
63
148
1557
—
—
—
17
73
133
1520
27
173
101
1216
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
4.4e-01
1.9e+00
—
—
—
—
7.6e-01
cases:3.70%
controls:2.41%
cases:5.56%
controls:0.86%
—
—
—
—
—
—
—
—
cases:7.81%
controls:3.82%
6
39
156
1581
9
14
153
1606
—
—
—
—
10
53
118
1336
Ultrasound examination of paranasal sinuses
SPAT1028 [2001700129]
1.9e+00
—
—
—
—
—
—
cases:4.32%
controls:0.68%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
155
1609
—
—
—
—
—
—
Observation for other suspected diseases and conditions
Z03.89 [2000503757]
1.8e+00
2.3e+00
—
—
—
—
1.3e+00
cases:6.17%
controls:1.11%
cases:3.09%
controls:0.31%
—
—
—
—
—
—
—
—
cases:7.03%
controls:2.09%
10
18
152
1602
5
5
157
1615
—
—
—
—
9
29
119
1360
Obesity due to excess calories
E66.01 [2000501501]
1.1e+00
—
—
—
—
—
1.7e+00
cases:4.32%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.15%
7
23
155
1597
—
—
—
—
—
8
16
120
1373
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
—
—
—
—
—
1.7e+00
7.3e-01
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:1.32%
cases:8.59%
controls:4.32%
—
—
—
—
—
10
21
140
1572
11
60
117
1329
combinations of corticosteroids
D07XB30 [21602188]
8.7e-01
9.9e-01
—
—
—
9.7e-01
8.0e-01
cases:20.99%
controls:10.00%
cases:8.64%
controls:3.40%
—
—
—
—
—
—
cases:8.00%
controls:3.20%
cases:21.09%
controls:10.73%
34
162
128
1458
14
55
148
1565
—
—
—
12
51
138
1542
27
149
101
1240
combinations of corticosteroids
D07AB30 [21602118]
8.7e-01
9.9e-01
—
—
—
9.7e-01
8.0e-01
cases:20.99%
controls:10.00%
cases:8.64%
controls:3.40%
—
—
—
—
—
—
cases:8.00%
controls:3.20%
cases:21.09%
controls:10.73%
34
162
128
1458
14
55
148
1565
—
—
—
12
51
138
1542
27
149
101
1240
fluconazole; oral, parenteral
J02AC01 [21603080]
6.0e-01
1.7e+00
—
—
—
1.6e+00
4.6e-01
cases:8.64%
controls:4.94%
cases:5.56%
controls:1.11%
—
—
—
—
—
—
cases:4.67%
controls:1.00%
cases:6.25%
controls:4.03%
14
80
148
1540
9
18
153
1602
—
—
—
7
16
143
1577
8
56
120
1333
Cathetrisation of artery
TPH07 [2001309747]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.03%
controls:1.44%
—
—
—
—
—
—
9
20
119
1369
Triglyceride [Moles/volume] in Serum or Plasma --fasting
47210-0 [3048773]
3.6e-01
3.1e-01
1.6e+00
—
7.5e-01
3.4e-01
3.9e-01
cases:29.01%
controls:22.22%
cases:16.05%
controls:12.35%
cases:6.17%
controls:1.30%
—
—
cases:3.11%
controls:1.49%
cases:18.67%
controls:14.00%
cases:51.56%
controls:41.83%
47
360
115
1260
26
200
136
1420
10
21
152
1599
—
5
24
156
1591
28
223
122
1370
66
581
62
808
metronidazole
D06BX01 [21602096]
1.6e+00
—
—
—
—
—
—
cases:5.56%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
—
—
9
19
153
1601
—
—
—
—
—
—
Erysipelas
A46 [45561706]
1.2e+00
—
—
—
—
—
1.6e+00
cases:4.94%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
cases:10.16%
controls:2.23%
8
24
154
1596
—
—
—
—
—
13
31
115
1358
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Blood
47598-8 [3048816]
1.0e+00
—
—
—
—
1.8e+00
1.6e+00
cases:3.09%
controls:1.11%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.56%
cases:8.59%
controls:1.87%
5
18
157
1602
—
—
—
—
5
9
145
1584
11
26
117
1363
metronidazole; vaginal
G01AF01 [21602392]
1.6e+00
—
—
—
—
—
—
cases:6.17%
controls:1.36%
—
—
—
—
—
—
—
—
—
—
—
—
10
22
152
1598
—
—
—
—
—
—
empagliflozin; oral
A10BK03 [1123740]
1.5e+00
1.5e+00
—
—
—
1.3e+00
8.4e-01
cases:4.94%
controls:1.11%
cases:5.56%
controls:1.23%
—
—
—
—
—
—
cases:5.33%
controls:1.44%
cases:6.25%
controls:2.81%
8
18
154
1602
9
20
153
1600
—
—
—
8
23
142
1570
8
39
120
1350
Spirometry study
18759-1 [3000492]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:1.80%
—
—
—
—
—
—
10
25
118
1364
Dyspnoea
R06.0 [45558449]
1.5e+00
1.3e+00
—
—
—
1.4e+00
3.9e-01
cases:11.11%
controls:2.65%
cases:3.09%
controls:0.86%
—
—
—
—
—
—
cases:4.00%
controls:1.00%
cases:6.25%
controls:4.32%
18
43
144
1577
5
14
157
1606
—
—
—
6
16
144
1577
8
60
120
1329
Cholesterol [Moles/volume] in Serum or Plasma
14647-2 [3019900]
3.0e-01
3.1e-01
1.5e+00
—
—
3.6e-01
2.5e-01
cases:29.63%
controls:23.83%
cases:18.52%
controls:14.26%
cases:7.41%
controls:1.73%
—
—
—
—
cases:22.67%
controls:17.01%
cases:53.13%
controls:46.94%
48
386
114
1234
30
231
132
1389
12
28
150
1592
—
—
34
271
116
1322
68
652
60
737
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
2.3e-01
3.1e-01
1.5e+00
—
—
3.6e-01
2.9e-01
cases:27.78%
controls:23.33%
cases:17.90%
controls:13.77%
cases:6.79%
controls:1.60%
—
—
—
—
cases:22.00%
controls:16.38%
cases:53.13%
controls:46.00%
45
378
117
1242
29
223
133
1397
11
26
151
1594
—
—
33
261
117
1332
68
639
60
750
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
5.1e-01
6.5e-01
1.5e+00
—
8.4e-01
5.3e-01
5.9e-01
cases:31.48%
controls:21.67%
cases:21.60%
controls:12.53%
cases:9.88%
controls:2.41%
—
—
cases:4.35%
controls:1.92%
cases:21.33%
controls:13.75%
cases:53.13%
controls:38.52%
51
351
111
1269
35
203
127
1417
16
39
146
1581
—
7
31
154
1584
32
219
118
1374
68
535
60
854
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
1.2e+00
—
—
—
—
1.6e+00
1.5e+00
cases:3.09%
controls:0.99%
—
—
—
—
—
—
—
—
cases:4.00%
controls:0.82%
cases:8.59%
controls:2.09%
5
16
157
1604
—
—
—
—
6
13
144
1580
11
29
117
1360
ABO and Rh group [Type] in Blood
882-1 [3003694]
1.9e-01
—
—
—
—
1.5e+00
4.5e-01
cases:4.94%
controls:4.14%
—
—
—
—
—
—
—
—
cases:6.67%
controls:1.63%
cases:7.81%
controls:5.11%
8
67
154
1553
—
—
—
—
10
26
140
1567
10
71
118
1318
Cortisol [Moles/volume] in Serum or Plasma
14675-3 [3036481]
1.3e+00
—
—
—
—
—
1.5e+00
cases:4.32%
controls:1.17%
—
—
—
—
—
—
—
—
—
—
cases:7.81%
controls:1.94%
7
19
155
1601
—
—
—
—
—
10
27
118
1362
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
1.4e+00
1.4e+00
—
—
—
1.4e+00
1.4e+00
cases:4.94%
controls:1.30%
cases:3.09%
controls:0.80%
—
—
—
—
—
—
cases:3.33%
controls:0.82%
cases:10.16%
controls:2.59%
8
21
154
1599
5
13
157
1607
—
—
—
5
13
145
1580
13
36
115
1353
Type 2 diabetes mellitus, with unspecified complications
E11.8 [45561951]
1.2e+00
—
—
—
—
1.7e+00
1.4e+00
cases:3.70%
controls:1.17%
—
—
—
—
—
—
—
—
cases:3.33%
controls:0.63%
cases:10.94%
controls:2.95%
6
19
156
1601
—
—
—
—
5
10
145
1583
14
41
114
1348
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
8.5e-01
1.5e+00
—
—
—
1.6e+00
1.4e+00
cases:6.79%
controls:3.02%
cases:5.56%
controls:1.36%
—
—
—
—
—
—
cases:5.33%
controls:1.13%
cases:18.75%
controls:5.54%
11
49
151
1571
9
22
153
1598
—
—
—
8
18
142
1575
24
77
104
1312
enoxaparin; parenteral
B01AB05 [21600976]
1.6e-01
1.1e+00
—
—
—
1.2e+00
1.3e+00
cases:6.79%
controls:5.86%
cases:5.56%
controls:1.98%
—
—
—
—
—
—
cases:5.33%
controls:1.69%
cases:15.63%
controls:4.97%
11
95
151
1525
9
32
153
1588
—
—
—
8
27
142
1566
20
69
108
1320
omeprazole; oral, parenteral
A02BC01 [21600096]
7.7e-01
8.9e-01
—
—
—
8.6e-01
1.2e+00
cases:6.79%
controls:3.27%
cases:3.09%
controls:1.30%
—
—
—
—
—
—
cases:3.33%
controls:1.44%
cases:10.94%
controls:3.46%
11
53
151
1567
5
21
157
1599
—
—
—
5
23
145
1570
14
48
114
1341
fusidic acid
D09AA02 [21602265]
1.2e+00
—
—
—
—
—
8.6e-01
cases:7.41%
controls:2.28%
—
—
—
—
—
—
—
—
—
—
cases:8.59%
controls:3.82%
12
37
150
1583
—
—
—
—
—
11
53
117
1336
fusidic acid; ointment
D06AX01 [21602062]
1.2e+00
—
—
—
—
—
8.6e-01
cases:7.41%
controls:2.28%
—
—
—
—
—
—
—
—
—
—
cases:8.59%
controls:3.82%
12
37
150
1583
—
—
—
—
—
11
53
117
1336
Urgent procedure
ZXD05 [2001311386]
9.1e-01
—
—
—
—
—
1.2e+00
cases:9.26%
controls:3.95%
—
—
—
—
—
—
—
—
—
—
cases:10.16%
controls:3.24%
15
64
147
1556
—
—
—
—
—
13
45
115
1344
Laceration/cut
S18 [2002000983]
5.7e-01
1.2e+00
—
—
—
9.4e-01
1.4e-01
cases:11.11%
controls:6.60%
cases:9.88%
controls:3.15%
—
—
—
—
—
—
cases:6.67%
controls:2.70%
cases:12.50%
controls:11.02%
18
107
144
1513
16
51
146
1569
—
—
—
10
43
140
1550
16
153
112
1236
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
1.3e+00
1.3e+00
—
—
—
1.6e+00
1.2e+00
cases:4.32%
controls:1.23%
cases:3.70%
controls:0.99%
—
—
—
—
—
—
cases:5.33%
controls:1.13%
cases:10.16%
controls:3.31%
7
20
155
1600
6
16
156
1604
—
—
—
8
18
142
1575
13
46
115
1343
Type 2 diabetes mellitus
E11 [45571656]
1.2e+00
9.4e-01
—
—
—
7.5e-01
8.9e-01
cases:17.90%
controls:6.23%
cases:7.41%
controls:3.02%
—
—
—
—
—
—
cases:4.67%
controls:2.26%
cases:14.84%
controls:6.70%
29
101
133
1519
12
49
150
1571
—
—
—
7
36
143
1557
19
93
109
1296
One hour or less
ZXE00 [2001311394]
4.9e-01
8.4e-01
—
—
—
1.4e+00
1.2e+00
cases:8.64%
controls:5.49%
cases:4.32%
controls:1.91%
—
—
—
—
—
—
cases:5.33%
controls:1.32%
cases:16.41%
controls:5.76%
14
89
148
1531
7
31
155
1589
—
—
—
8
21
142
1572
21
80
107
1309
Rheumatology
66 [38004491]
2.5e-01
—
—
—
—
8.4e-01
1.1e+00
cases:4.32%
controls:3.40%
—
—
—
—
—
—
—
—
cases:4.00%
controls:1.76%
cases:10.16%
controls:3.46%
7
55
155
1565
—
—
—
—
6
28
144
1565
13
48
115
1341
Neurology
13 [38004458]
-8.1e-02
4.8e-01
—
—
-1.0e+50
1.1e+00
7.0e-01
cases:9.88%
controls:10.62%
cases:5.56%
controls:3.52%
—
—
—
—
cases:0.00%
controls:0.56%
cases:11.33%
controls:3.95%
cases:19.53%
controls:10.80%
16
172
146
1448
9
57
153
1563
—
—
0
9
161
1606
17
63
133
1530
25
150
103
1239

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
45
12
51.54
74.98
1.8
1.2
—
—
—
0
0
64
79
12.74
52.23
3.0
1.9
1.24
1.64
g/l
0.43
58
73
86
156
10.62
51.94
5.3
2.6
2.31
1.65
%
2.78
80
139
70
109
10.55
47.49
4.5
2.6
0.18
0.22
g/l
2.32
65
101
73
124
9.90
45.95
6.1
2.5
83.64
66.30
e9/l
2.12
58
89
60
87
10.37
42.71
2.0
1.8
—
—
—
0
0
38
39
12.42
34.37
1.3
1.1
—
—
—
0
0
124
464
8.13
33.91
19.1
5.8
—
—
—
0
0
36
38
11.89
31.84
2.3
3.6
1.77
2.08
ratio
0.13
22
19
77
195
6.62
31.73
4.3
2.4
21.96
23.84
%
0.45
72
183
30
27
13.41
29.32
1.7
1.3
—
—
—
0
0
42
63
8.65
28.30
3.0
1.7
0.79
1.51
g/l
5.38
30
55
68
185
5.61
25.09
1.9
1.5
—
—
—
0
0
136
667
7.47
24.38
20.8
6.2
2.93
2.76
%
0.23
131
636
136
668
7.45
24.31
21.1
6.4
0.82
0.69
%
0.54
131
633
136
672
7.38
24.02
21.5
6.5
9.04
8.76
%
0.44
131
642
74
224
5.24
23.92
2.1
1.6
—
—
—
0
0
29
9
38.81
23.35
1.2
1.0
—
—
—
0
0
98
380
5.00
23.05
10.7
4.7
—
—
—
0
0
68
201
5.11
22.41
1.8
1.4
517.33
525.45
titre
0.01
15
44
27
9
35.60
21.36
1.1
1.0
—
—
—
0
0
52
128
5.51
21.13
1.6
1.5
—
—
—
0
0
29
39
8.84
21.09
1.5
1.3
—
—
—
0
0
131
672
5.96
20.77
20.0
6.3
58.35
58.07
%
0.09
126
648
50
121
5.53
20.68
1.8
1.3
—
—
—
0
0
85
316
4.56
20.60
3.5
2.1
3.40
2.83
mg/l
1.18
75
277
59
167
4.98
20.26
9.9
2.9
11.76
4.88
umol/l
2.84
52
145
47
110
5.61
20.14
10.4
5.8
0.83
0.28
%
1.25
35
38
138
751
6.65
20.02
20.4
6.3
0.21
0.19
e9/l
0.24
121
659
48
117
5.41
19.60
11.3
5.7
1.28
0.95
%
0.32
37
43
136
743
6.17
19.29
19.4
6.3
1.54
1.87
e9/l
2.38
126
657
134
736
5.75
18.53
19.3
6.1
0.55
0.58
e9/l
0.16
121
632
134
737
5.73
18.47
19.2
6.1
0.05
0.04
e9/l
0.24
120
632
29
21
16.54
18.13
2.1
5.1
—
—
—
0
0
79
301
4.17
18.03
2.7
1.4
2.52
2.55
g/l
0.03
62
180
141
821
6.53
17.75
25.4
9.5
4.36
4.16
e9/l
0.14
130
708
44
108
5.22
17.70
11.2
6.0
0.15
0.18
%
0.09
33
34
73
280
3.93
16.18
2.2
1.8
—
—
—
0
0
59
196
4.16
16.02
2.1
1.7
1253.33
1203.06
nmol/l
0.14
47
161
43
112
4.87
16.01
11.9
6.7
0.31
0.26
%
0.06
32
34
27
26
12.22
14.92
1.9
1.2
148.60
169.29
au/ml
—
5
7
22
13
19.35
14.78
2.7
1.8
35.71
42.78
%
0.78
22
13
19
7
30.45
14.65
3.8
2.6
1460.21
708.57
u/ml
—
19
7
114
619
3.84
14.37
27.7
12.5
1.37
1.22
inr
2.18
105
520
20
10
22.57
14.18
1.2
1.4
—
—
—
0
0
119
669
3.93
14.12
16.2
7.7
1.19
1.21
mmol/l
1.88
105
593
25
23
12.63
14.10
1.6
1.2
272.50
175.36
u/ml
0.53
12
14
25
29
9.98
12.57
1.1
1.3
—
—
—
0
0
89
447
3.20
12.05
5.7
2.8
57.30
72.91
u/l
0.51
83
417
56
222
3.33
11.18
3.8
2.5
—
—
—
0
0
27
65
4.78
10.84
2.7
3.1
14.06
7.44
iu/ml
—
5
15
48
177
3.43
10.71
1.6
1.3
—
—
—
0
0
20
37
6.03
10.70
1.1
1.3
—
—
—
0
0
20
21
10.69
10.61
1.1
1.0
—
—
—
0
0
86
449
2.95
10.47
8.0
2.3
—
—
—
0
0
22
47
5.26
10.11
2.3
1.9
1.08
1.16
g/l
0.61
22
47
18
17
11.75
10.07
1.2
1.0
—
—
—
0
0
43
157
3.37
9.66
1.9
1.8
—
—
—
0
0
37
129
3.42
8.89
13.8
8.4
—
—
—
0
0
79
423
2.69
8.76
9.0
4.0
7.40
7.40
ph
0.06
66
308
22
55
4.47
8.38
2.6
1.8
2.05
1.36
ug/l
0.19
22
49
13
9
15.56
8.36
1.5
1.7
3.94
4.60
mg/l
—
13
9
24
67
4.03
7.92
5.4
3.2
—
—
—
0
0
95
583
2.52
7.61
3.1
2.0
101.58
95.66
pmol/l
0.43
61
298
103
658
2.55
7.55
7.4
2.9
—
—
estimate
—
0
0
14
15
10.09
7.45
4.9
1.3
33.00
34.00
pg
0.37
14
15
61
313
2.52
7.09
4.2
2.7
4.96
3.96
e6/l
0.25
61
285
40
171
2.78
6.66
10.6
10.3
7.42
7.42
ph
0.02
23
108
12
12
10.69
6.65
2.9
3.1
43.22
40.27
%
—
6
6
60
315
2.44
6.55
3.0
1.6
1.62
1.00
mg/l
0.89
47
248
36
147
2.86
6.52
7.2
3.5
1.71
1.88
mmol/l
0.13
31
123
13
16
8.72
6.47
1.2
1.3
—
—
—
0
0
12
13
9.86
6.41
2.3
1.1
—
—
—
0
0
37
155
2.80
6.38
7.5
3.6
7.37
7.38
ph
0.71
26
98
9
5
18.94
6.34
2.8
1.4
22.44
23.40
%
—
9
5
9
5
18.94
6.34
1.2
1.0
—
—
—
0
0
39
169
2.72
6.30
10.4
10.4
0.98
1.25
mmol/l
0.15
34
144
24
80
3.35
6.10
10.8
14.4
14.45
15.87
%
1.96
24
80
9
6
15.77
5.97
1.0
1.7
—
—
—
0
0
12
15
8.54
5.95
1.3
1.3
6.52
5.53
g/l
—
7
9
12
15
8.54
5.95
1.3
1.3
0.59
0.36
g/l
—
7
9
14
23
6.55
5.84
5.3
3.3
3.87
4.52
e9/l
0.23
14
23
77
469
2.22
5.80
5.4
3.2
43.09
168.29
e6/l
0.42
63
352
12
16
8.00
5.74
1.3
1.3
—
—
—
0
0
11
13
8.98
5.65
1.5
1.0
—
—
—
0
0
16
34
5.10
5.47
6.1
3.1
58.38
60.56
%
0.18
16
34
14
26
5.79
5.36
1.3
2.5
0.44
1.03
g/l
—
9
20
82
524
2.14
5.36
6.4
3.7
52.63
92.64
e6/l
0.49
65
367
39
184
2.47
5.25
2.6
1.6
—
—
—
0
0
23
82
3.10
5.24
13.8
8.3
24.27
24.94
mmol/l
0.32
23
82
64
377
2.15
5.11
4.6
3.0
—
—
—
0
0
67
403
2.13
5.06
5.4
3.1
0.25
0.46
e6/l
1.05
52
288
59
340
2.16
4.95
13.1
5.3
—
—
—
0
0
32
145
2.50
4.66
11.7
11.6
111.44
122.01
g/l
2.01
32
145
21
76
3.03
4.66
2.1
1.4
0.25
0.33
mg/l
—
10
35
7
5
14.54
4.62
4.3
2.2
0.64
0.61
mmol/l
—
7
5
32
147
2.47
4.52
2.6
5.1
2.69
35.07
ug/l
0.61
27
126
35
172
2.32
4.26
1.6
1.4
—
—
—
0
0
55
330
2.01
4.02
1.4
1.3
0.89
1.20
u/ml
0.31
15
102
22
89
2.70
4.00
4.1
9.6
—
—
—
0
0
29
135
2.40
3.97
1.6
1.6
—
—
—
0
0
11
24
4.84
3.82
2.2
1.8
—
—
—
0
0
11
24
4.84
3.82
2.2
1.8
—
—
—
0
0
11
24
4.84
3.82
2.2
1.7
—
—
—
0
0
11
24
4.84
3.82
2.2
1.8
—
—
—
0
0
8
12
6.95
3.72
1.0
1.3
—
—
—
0
0
64
415
1.90
3.68
13.0
6.1
—
—
—
0
0
33
169
2.20
3.62
4.9
3.8
8.83
5.54
e9/l
0.40
28
148
37
199
2.11
3.59
13.6
6.8
103.30
104.10
mmol/l
0.45
37
199
88
637
1.84
3.53
34.2
11.0
0.08
0.00
e9/l
0.78
78
516
40
225
2.03
3.45
3.9
2.9
1.89
1.66
e6/l
0.09
18
113
13
38
3.63
3.40
7.8
3.0
7.39
7.42
ph
1.08
13
38
21
91
2.50
3.34
4.8
2.5
2.20
1.41
%
0.86
21
91
9
19
4.95
3.29
1.1
1.2
—
—
—
0
0
11
29
3.99
3.25
7.0
22.7
104.91
105.62
mmol/l
0.17
11
29
11
29
3.99
3.25
7.0
22.7
10.82
10.69
mmol/l
0.04
11
29
8
15
5.55
3.23
1.0
1.3
—
—
—
0
0
8
15
5.55
3.23
2.3
2.0
—
—
—
0
0
20
87
2.48
3.16
1.8
1.2
—
—
—
0
0
6
8
7.73
3.08
1.2
1.1
—
—
—
0
0
98
753
1.76
3.05
5.7
3.6
88.72
0.00
estimate
0.79
29
168
5
5
10.26
3.00
1.2
1.0
—
—
—
0
0
81
593
1.73
2.96
4.7
3.3
6.17
6.14
ph
0.12
46
353
8
17
4.89
2.96
1.8
2.4
—
—
—
0
0
76
547
1.73
2.95
7.7
3.8
27.54
36.15
ng/l
0.55
61
385
10
27
3.88
2.93
8.5
2.4
7.86
8.72
kpa
—
10
27
10
27
3.88
2.93
8.5
2.4
4.78
4.86
kpa
—
10
27
96
744
1.71
2.80
5.8
3.6
0.00
0.00
estimate
-0.00
27
165
13
48
2.86
2.79
1.8
2.7
—
—
—
0
0
5
6
8.55
2.77
4.8
1.0
—
—
—
0
0
97
756
1.71
2.75
5.7
3.7
0.00
0.00
estimate
-0.00
25
151
6
10
6.18
2.72
1.3
1.1
—
—
—
0
0
7
15
4.82
2.62
3.1
1.7
8.54
10.71
%
—
7
15
40
247
1.82
2.58
1.4
1.3
37.35
4.60
u/ml
—
10
100
5
7
7.32
2.56
1.2
1.3
—
—
iu/ml
—
0
0
65
463
1.67
2.54
5.7
4.2
33.85
11.48
mg/mmol
0.85
44
309
9
26
3.60
2.52
2.1
2.8
—
—
—
0
0
19
90
2.26
2.50
1.2
1.2
26.89
138.63
u/ml
—
8
32
10
32
3.26
2.48
8.0
2.6
—
—
—
0
0
6
12
5.15
2.42
1.0
1.1
—
—
—
0
0
7
18
4.01
2.28
1.3
1.2
—
—
—
0
0
18
87
2.20
2.27
4.7
2.5
0.70
0.61
%
0.65
18
87
62
448
1.62
2.24
4.4
3.5
213.38
68.16
mg/l
1.00
42
307
5
9
5.69
2.23
1.6
1.2
—
—
—
0
0
11
42
2.73
2.19
1.2
1.2
—
—
—
0
0
42
276
1.70
2.17
1.5
1.3
124.81
34.24
iu/ml
0.54
16
88
73
553
1.58
2.15
2.2
2.0
—
—
—
0
0
40
576
0.59
2.14
3.5
3.2
—
—
—
0
0
8
25
3.31
2.12
1.4
1.5
—
—
—
0
0
59
428
1.60
2.07
3.4
2.0
103.59
225.35
u/l
1.96
59
410
6
15
4.11
2.06
1.2
1.2
—
—
—
0
0
58
421
1.59
2.02
6.5
3.6
3.13
0.00
estimate
0.48
24
151
64
477
1.56
1.99
4.5
3.3
7.04
8.29
mmol/l
1.72
54
407
6
16
3.85
1.95
1.3
1.3
—
—
—
0
0
39
259
1.67
1.93
5.6
3.8
584.23
489.35
ng/l
0.06
33
203
120
1034
1.62
1.93
5.0
4.2
14.68
14.86
pmol/l
0.41
113
956
5
12
4.26
1.83
1.4
1.5
—
—
—
0
0
19
103
1.96
1.81
3.2
2.3
17.28
9.39
ug/l
0.35
13
92
55
404
1.55
1.79
1.8
1.4
—
—
—
0
0
13
62
2.19
1.71
1.2
1.1
—
—
—
0
0
149
1381
1.98
1.58
54.9
15.5
23.18
24.38
mg/l
0.21
144
1127
61
471
1.47
1.54
6.0
3.5
—
—
—
0
0
12
59
2.12
1.47
2.9
2.3
—
—
—
0
0
55
420
1.47
1.46
5.2
3.1
10.87
0.01
estimate
0.48
23
128
6
22
2.79
1.45
11.3
3.4
13.93
9.36
pmol/l
—
6
22
45
332
1.49
1.41
5.2
3.5
1.02
1.02
kg/l
0.61
32
217
70
569
1.41
1.30
6.0
3.5
0.00
0.00
estimate
-0.00
25
134
5
18
2.83
1.29
4.4
3.4
3.42
3.09
nmol/l
—
5
18
6
25
2.45
1.25
1.3
1.1
—
—
—
0
0
6
25
2.45
1.25
3.7
1.8
—
—
—
0
0
6
25
2.45
1.25
1.3
1.1
—
—
—
0
0
15
90
1.73
1.08
1.4
1.3
—
—
—
0
0
5
22
2.31
1.04
3.4
1.1
—
—
—
0
0
127
1356
0.71
0.97
6.1
4.9
1.17
1.43
mmol/l
11.40
120
1271
21
144
1.53
0.93
2.9
1.5
—
—
—
0
0
25
179
1.47
0.91
1.0
1.2
—
—
—
0
0
122
1303
0.74
0.83
6.0
4.2
1.44
1.30
mmol/l
1.21
114
1217
0
27
0.00
0.78
0.0
3.3
—
18.78
—
0
27
17
116
1.52
0.78
10.0
3.6
—
—
—
0
0
131
1381
0.73
0.77
6.6
5.7
2.28
2.70
mmol/l
6.45
125
1294
125
1163
1.33
0.76
65.1
19.2
15.12
13.54
%
10.12
125
1156
129
1362
0.74
0.75
6.2
5.0
4.03
4.60
mmol/l
8.87
123
1283
7
42
1.70
0.69
1.7
1.2
—
—
—
0
0
136
1289
1.34
0.66
9.3
6.3
39.37
39.44
mmol/mol
0.02
126
1231
17
121
1.45
0.65
2.8
2.7
0.07
0.78
e6/l
0.48
17
115
11
71
1.59
0.64
5.0
4.0
37.02
37.00
°c
0.06
11
71
5
30
1.69
0.62
1.8
1.2
0.93
0.88
nmol/l
—
5
24
0
20
0.00
0.61
0.0
1.1
—
1.80
—
0
7
0
21
0.00
0.60
0.0
1.0
—
0.77
—
0
11
133
1265
1.29
0.56
6.3
5.0
2.10
1.93
mu/l
0.71
125
1172
13
168
0.75
0.38
1.7
1.4
—
—
—
0
0
15
124
1.23
0.25
1.2
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
0.14
—
0
7
0
13
0.00
0.21
0.0
1.2
—
169.03
—
0
13
6
49
1.23
0.20
3.0
1.1
0.69
0.86
g/l
—
6
49
29
319
0.89
0.18
3.1
3.0
0.72
0.74
ug/l
0.06
20
206
6
75
0.79
0.16
1.7
1.8
—
—
—
0
0
145
1429
1.14
0.14
48.5
13.8
—
—
—
0
0
6
57
1.05
0.08
1.0
1.0
—
—
—
0
0
133
1321
1.04
0.02
7.1
4.9
6.46
5.95
mmol/l
2.08
125
1228
12
119
1.01
0.00
1.9
2.1
6.00
6.12
ph
—
5
83
15
153
0.98
0.00
2.5
2.4
11.25
13.94
nmol/l
0.78
15
144
6
59
1.02
0.00
3.7
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
32.08
—
0
5
0
5
0.00
0.00
0.0
1.2
—
29.00
—
0
5
0
5
0.00
0.00
0.0
1.0
—
7.12
—
0
5
6
60
1.00
0.00
3.8
1.5
—
—
—
0
0
6
59
1.02
0.00
3.7
1.5
—
—
—
0
0
0
5
0.00
0.00
0.0
2.6
—
1.75
—
0
5
0
8
0.00
0.00
0.0
1.1
—
0.00
—
0
8
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
143.33
—
0
6
6
61
0.98
-0.00
3.8
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
49.50
—
0
6
6
61
0.98
-0.00
3.5
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.2
—
17.72
—
0
6

Mortality – FinRegistry

↥

Association

Association between endpoint D3_HYPERSPLENISM and mortality.

Females

Parameter HR [95% CI] p-value
D3_HYPERSPLENISM 6.062 [3.72, 9.87] < 0.001
Birth year 0.995 [0.99, 1.0] 0.274

During the follow-up period (1.1.1998 — 31.12.2019), 136 out of 361 females with D3_HYPERSPLENISM died.

Males

Parameter HR [95% CI] p-value
D3_HYPERSPLENISM 4.648 [3.31, 6.52] < 0.001
Birth year 0.986 [0.98, 1.0] 0.004

During the follow-up period (1.1.1998 — 31.12.2019), 174 out of 469 males with D3_HYPERSPLENISM died.

Mortality risk

Mortality risk for people of age

years, who have D3_HYPERSPLENISM.

N-year risk Females Males
1 0.658% 0.829%
5 3.469% 5.303%
10 8.399% 13.102%
15 16.608% 22.798%
20 27.309% 36.245%

Relationships between endpoints

↥

Index endpoint: D3_HYPERSPLENISM – Hypersplenism

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data